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ABSTRACT
THE ANTITUMOR AGENT, ARGLABIN-DMA, PREFERENTIALLY INDUCES 
APOPTOSIS IN HUMAN COLON TUMOR CELLS
Sung Wook Kwon 
Old Dominion University, 2005 
Director: Dr. Christopher J. Osgood
Arglabin-DMA, an analog o f famesyl pyrophosphate (FPP), reportedly inhibits 
famesyltransferase (FTase) directly by competitively blocking the binding of Ras protein 
and its posttranslational modification, as suggested in previous studies. But, the 
mechanisms by which Arglabin-DMA inhibits tumor growth in vivo and in vitro are still 
relatively poorly characterized. To determine the mechanism by which this drug inhibits 
tumor growth, the effects o f Arglabin-DMA in two human colon tumor cell lines (mutant 
K-ras HCT 116 and wild-type ras HT-29) were explored on cell proliferation, apoptosis, 
and cell cycle kinetics in vitro. In cell viability studies, we showed that Arglabin-DMA 
had striking morphological and physiological effects on the two human colon tumor cell 
lines, possibly more so than those of other anticancer drugs. Also, Arglabin-DMA 
exhibited less harm to normal cells (Hs27) which retained their potential for cell growth. 
An add-back experiment showed that Arglabin-DMA had no effect on the isoprenoid 
biosynthetic pathway. The drug not only affects the mutant K-ras human colon tumor cell 
line, but also the wild-type ras human colon tumor cell line. It may therefore inhibit one 
or more non-Ras proteins to exert its antitumor effects. Gel electrophoresis, TUNEL 
assay, Annexin V assay, apoptosis dye-uptake assay, and morphological criteria were
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
used to characterize apoptosis. Adherent cells and freely floating detached cells in 
Arglabin-DMA treatment were treated as two distinct populations. We demonstrated that 
the detached cells caused by Arglabin-DMA exposure exhibited increased apoptosis in a 
p53-independent manner. Cell cycle effects were studied using flow cytometry. After 
Arglabin-DMA was added, the proportion of the two human colon tumor cells in G2 /M 
phase increased, indicating a block in either G2 or M phase. We conclude that Arglabin- 
DMA has specific cytotoxic effects in two human colon tumor cell lines, and less 
cytotoxicity to normal cells. It induces arrest at the G2/M phase o f the cell cycle. After 
treatment with Arglabin-DMA, rounded and detached cells enter apoptosis. This 
mechanism may be analogous to "anoikis," which is the induction o f apoptosis in 
response to loss of cell contact. The utility o f this drug in combating cancer remains an 
attractive, though complex possibility.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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INTRODUCTION
1. CANCER AND RAS
Normal cells grow, divide, and die in an orderly fashion. The cells o f most tissues 
divide only to replace worn-out or dying cells, or to repair injuries. However, cancer cells 
continue to grow and divide, exhibiting uncontrolled growth. They can spread to other 
parts of the body via the bloodstream, or lymph system. These cells accumulate and form 
tumors.
Different types of cancers, named for the organ or type o f cell in which they 
originated, vary in their rates of growth, patterns o f dispersal, and responses to different 
types o f treatment. That is why people with cancer require treatment that is targeted 
towards their specific form of the disease. The number of treatment choices depends on 
the type o f cancer, the stage o f the cancer, and other individual factors such as age, health 
status, and personal preferences.
Presently, the three major types o f treatment for cancer are surgery, radiation, and 
chemotherapy. Chemotherapy involves the use o f drugs to kill tumor cells. The several 
classes of chemotherapeutic drugs act by various means, most frequently by inhibiting 
the ability of tumor cells to divide. Therapeutic drugs are commonly used in combination
The model for this dissertation is British Journal of Cancer.
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to attack these tumors, as these cells are less able to withstand a variety o f agents 
attacking in different ways. The compounds may be introduced into the body 
systemically, or they may be concentrated at the tumor site (Ampil et al., 1999).
New approaches for chemotherapy were developed using the characteristic 
molecular abnormalities o f cancers. Recently, researchers have studied the molecular 
defects that transform normal cells into malignant cells. They found that many of these 
defects consist of mutations in key classes o f genes that are responsible in some way for 
the growth and replication of cells (Gatenby and Maini, 2002). These mutations alter the 
behavior of proteins encoded by growth-regulating genes and disrupt the functions that 
control cell division. The discovery o f mutant genes is enabling pharmaceutical 
researchers to design new drugs that will act specifically on these disrupted genes, or 
their proteins. The defects targeted by molecular therapy are found in three classes of 
genes: oncogenes, which stimulate cell progression through the cell cycle; tumor 
suppressor genes restricting this growth; and genes governing the replication and repair 
o f DNA. Most tumors possess mutations in one or more of these gene categories (Oliff, 
1999).
A detailed understanding o f the mechanisms by which genetic mutations appear 
to have increased cancerous risk to the cell is anticipated to result in mechanism-based 
cancer therapeutics. These therapies specifically target the underlying defects in cellular 
growth regulation. Compared to current chemotherapeutic agents, these alternative
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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therapeutics may prove to be much less toxic and more effective, thus possibly producing 
superior therapeutic results. One potential target is the Ras protein, which is mutationally 
activated in a large range of human tumors and is an important contributor to the 
neoplastic phenotype (Bos, 1998; Rowinsky et a i,  1999).
The Ras superfamily consists o f over 150 small GTPase proteins. This 
superfamily contains monomeric proteins that bind GDP (guanine diphosphate) and GTP 
(guanine triphosphate) and may be found in the plasma membrane and nuclear envelope. 
Within the superfamily there are six subfamilies: Ras, Rho, Ran, Rab, Arf, and Kir/Rem. 
Although many Ras members can interact with the same effector molecules, the 
physiological roles o f most Ras-like GTPases are not fully understood (Bos, 1997;
Ehrhart et al., 2002).
The distinct members of the Ras superfamily are involved in a wide diversity of 
cellular functions, the Ras and Rho groups being of special interest. Both the Ras and 
Rho families mediate key cellular processes in response to diverse stimuli such as cell 
growth, differentiation, apoptosis, lipid metabolism, cytoarchitecture, membrane 
trafficking, and transcriptional regulation. However, the negative aspect o f these 
multifunctional proteins arises by way o f point mutations, overexpression, or insensitivity 
to regulatory signals. This results from the ability of these GTPases to trigger specific 
signals, which lead to uncontrolled cell growth, enhanced angiogenesis, inhibition of
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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apoptosis, and genetic instability. Collectively, these mutations can result in tumor 
development (Rechavi et al., 1989; Vermes and Haanen, 1994).
The members o f Ras family, at least 13 at present, are characterized by extensive 
similarities in their effector domains (Lowy and Willumsen, 1993). Besides three Ras 
proteins (H-Ras, K-Ras, and N-Ras) that share about 85% sequence identity, two other 
Ras proteins (M-Ras and R-Ras), four Rap proteins (RaplA, Rap IB, Rap2A, and Rap2B), 
two Ral proteins (RalA and RalB), TC21, and Rheb are classified in the Ras family. The 
other members, except the three Ras proteins (H-Ras, K-Ras, and N-Ras), share at least 
40-50% amino acid identity with p21 Ras (Adjei, 2001; Beaupre and Kurzrock, 1999).
The Ras family as a whole acts as molecular switches that regulate a wide range o f cell 
functions, including proliferation and differentiation (Gibbs et al., 1994; Moores et al., 
1991; Tamanoi, 1993).
The Rho family of proteins share at least 30% sequence identity, and include 
several members: Rho A, Rho B, Rho C, Rho D, Rho E, Rho G, TC10, Rac 1 A, Rac IB, 
Rac 2, CDC42Hs, and G25K (Takai et al., 1995). These proteins play critical roles in the 
regulation o f the cytoskeleton as well as in signal transduction of different stimuli 
(Hernandez-Alcoceba et al., 2000; Takai et al., 2001).
Ras and Rho family members exhibit a carboxy-terminal CAAX motif, where a 
cysteine is followed by two aliphatic residues and one random amino acid. This m otif is a 
target for processing by enzymes, which results in the addition of a carboxy-terminal
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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prenyl group. Either a farnesyl or a geranylgeranyl moiety is involved in anchoring Ras 
to membranes (Casey, 1995). Inhibitors o f the enzymes involved in this prenylation 
process show promise as inhibitors o f Ras function by blocking its localization to the 
plasma membranes (Ehrhardt et al., 2002; Reuter et al., 2000).
In isoprenoid biosynthesis in mammalian cells, the FPP (farnesyl pyrophosphate) 
comprises 15 carbon chains. Also two molecules o f the 10-carbon GPP (geranyl 
pyrophosphate) combine to form the 20-carbon GGPP (geranylgeranyl pyrophosphate) 
(Adjei, 2001). GPP and FPP are intermediates in the synthesis of monoterpenes and 
sesquiterpenes. Assorted monoterpenes and sesquiterpenes posttranscriptionally down- 
regulate HMG-CoA (3 -hydroxy-3-methyglutaryl coenzyme A) reductase activity, a key 
activity in the isoprenoid biosynthetic pathway (the mevalonate pathway). The 
isoprenoid-mediated suppression of mevalonate synthesis depletes tumor tissues o f two 
intermediate products, GGPP and FPP, which are incorporated posttranslationally into 
growth control-associated proteins. Isoprenoids targeted to the inhibition of the 
isoprenylation of oncogenic forms o f ras proteins may offer a novel approach to 
chemotherapy (Elson, 1995) (Figure 1).
Two mevalonic acid pathway intermediates, GGPP and FPP, are substrates for 
protein isoprenyl transferases. These enzymes catalyze the formation of thioester bonds 
between the carbon chains of isoprenyl pyrophosphates and cysteine residues located 
near the carboxy terminals of a variety o f proteins that include the nuclear lamins and the





















Geranylgeranyl Protein Cholesterol Farnesylated Protein
Figure 1 The isoprenoid biosynthetic pathway. Mevalonate is used as a precursor in 
metabolic labeling studies. Lovastatin blocks this pathway by the inhibition of HMG- 
CoA (3-hydroxy-3-methyglutanyl coenzyme A) reductase. GPP (Geranyl pyrophosphate), 
FPP (farnesyl pyrophosphate), and GGPP (geranylgeranyl pyrophosphate) are produced 
from mevalonate. FPP is responsible for the post-translational modification and 
membrane targeting of Ras protein, whereas GGPP is responsible for those of Rho family 
small GTP-binding protein. FTI (Famesyltransferase inhibitor) or GGTI 
(Geranylgeranyltransferase Inhibitor) block famesylation or geranylgeranylation to 
modify Ras or Rho. FPP is an intermediate in the synthesis o f sesquiterpenes. Some 
sesquiterpenes like Arglabin-DMA inhibit famesylation. (Elson, 1995; Holstein et al., 
2002; Maltese, 1990).
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small and large G-proteins (Clarke, 1992). The development of inhibitors targeted to the 
Ras protein famesyltransferase (FTase) offers an approach to the control of the growth of 
certain tumors (Goldstein and Brown, 1990).
The oncogenic ras genes in human cells have been identified, and are called H- 
ras, 'H-ras, and K-rav. These ras oncogenes encode four 21-kD proteins, called P21ras or 
Ras (H-Ras, N-Ras, and K-Ras4A and K-Ras4B, resulting from two alternatively spliced 
K-ras gene products) (Rowinsky et al., 1999). Ras proteins consist of 188 or 189 amino 
acids that are highly conserved in the N and C termini. Most o f the differences between 
these proteins occur in the near C-terminal hypervariable domain o f about 25 amino acids, 
which is presumed to be responsible for their different functions (Adjei, 2001).
Ras is synthesized as a propeptide which undergoes a series of posttranslational 
lipid modifications that enable it to associate with the inner surface o f the plasma 
membrane. The first step in posttranslational modification is mediated by FTase (farnesyl 
transferase), which transfers a farnesyl moiety from FPP to the cysteine moiety in the 
CAAX motif at the carboxyl terminus of Ras (Rowinsky et al., 1999) (Figure 2). After 
famesylation, CAAX proteins undergo cleavage o f the AAX by CAAX protease. The 
exposed carboxyl group of the famesyl-cysteine is carboxymethylated by a SAM (S- 
adenosyl-L-methionine) donor. In some Ras proteins, palmitoyl transferase catalyzes an 
additional modification of upstream cysteine residues by the fatty acid palmitate. These 
modifications enhance protein hydrophobicity and plasma membrane association (Adjei,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
8
H ,a  x h .
0  o  
0\(J/Ov.jJ/OH
1 I 




R as— 0 ------- A-
H ,C .
R as— C-
F T a se
CAAX: C represents a cysteine residue; A represent aliphatic amino acids, usually valine, 
leusine, or isoleucine; and X is either methionine or serine
Figure 2 Ras posttranslational modification. The first step is mediated by 
famesyltransferase (FTase), which transfers a farnesyl moiety from farnesyl 
pyrophosphate (FPP) to the cysteine moiety in the CAAX motif at the carboxyl terminus 
o f Ras. FTase inhibitions block this enzymatic step (Rowinsky et al., 1999).
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2001; Gibbs and Oliff, 1997). A closely related enzyme, protein GGTase (geranylgeranyl 
transferase), recognizes the C-terminal CaaX motif present in proteins such as Rho A. 
After geranylgeranylation that transfers a geranylgeranyl moiety from GGPP to the 
cysteine moiety in the CAAX motif at the carboxyl terminus o f target protein, these 
proteins undergo modifications that facilitate membrane association similar to Ras 
posttranslational lipid modifications (Tamanoi et al., 2001) (Figure 3). Many mammalian 
proteins, besides the four forms o f Ras, have a CAAX motif and are substrates for either 
FTase or GGTase (Rowinsky et al., 1999) (Table 1).
Ras is activated in response to a variety o f extracellular signals resulting in 
stimulation of tyrosine protein kinases, either directly or indirectly. Ras proteins function 
as molecular switches, and are determined by whether they are bound to GDP or GTP, 
conferred by the small GTPase (Ehrhardt et al., 2002). The small GTPase, which cycles 
between active GTP-bound and inactive GDP-bound states, is activated by GEFs 
(guanine nucleotide exchange factors). GEFs include the SOS (son o f sevenless) proteins 
and Cdc25. In the receptor tyrosine kinase cascade, the adaptor protein, Grb2 (growth 
factor receptor-binding protein), binds to activated receptors via its SH2 domain, then 
recruits GEFs to the cell membrane via its SH3 domain (Takai et al., 2001). In its GTP- 
bound state, Ras interacts with several downstream effector pathways which contain 
multiple internal branch points. Raf is one o f many effectors o f Ras signaling. Other 
effectors include proteins Rac and Rho, and PI3K (phosphatidylinositol-3’-kinase), and 
MEKK (mitogen-activated protein kinase kinase kinase). The activation o f the effector 
Raf phosphorylates MEK (mitogen-activated protein kinase kinase), which in turn
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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^ a a x P a l CoA S — Farnesyl
p p p  -CaaX(S, M, Q)
FTase
— V __ *  V  j f  — C — OMe
Caboxylmethyl Palmitoyl





— C — OMe
-CaaX(L)
SAI Pal Co,
Figure 3 Posttranslational modifications o f CaaX-containing proteins. FTase 
famesylates CaaX substrates having C-terminal residues Ser, Met, and Gin (S, M, and Q). 
GGTase-I prefers CaaX substrates having a C-terminal Leu (L). (SAM, S-adenosyl-L- 
methionine; FPP, farnesyl pyrophosphate; GGPP, geranylgeranyl pyrophosphate) (Gibbs 
and Oliff, 1997).
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Table 1 Famesylated or geranylgeranylated CAAX proteins
Farnesylated CAAX Protein(s) Geranylgeranylated CAAX Protein(s)
H-ras, K4B-Ras, and N-ras G-proteins y-subunits
Lamins A and B Rap 1
Rap2 Rho A, B, C, and G
R hoE Cdc42
Pxf Rac 1 and 2
Phosphorylase kinase a  and (5 R-Ras 1 and R-Ras 2/TC21
PRL-1/PTP CAAX 1 and 2 Ral A and B
Transducin y cGMP phosphodiesterase (3
cGMP phosphodiesterase a 2’-3’ ologo (A) synthetase 3’-
phosphodiesterase





Mammalian CAAX proteins that are known or likely to be prenylated. Data adapted from 
(Rowinsky et al., 1999).
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phosphorylates MAPK (mitogen-activated protein kinase), and ERK (extracellular signal- 
regulated kinase). Upon activation, MAPKs/ERKs stimulate transcription and 
proliferation. MEKK activates SEK1, which in turn phosphorylates another MAPK 
family number, JUN (jun amino-terminal kinase). It promotes apoptosis and proliferation. 
Activation of Rac and Rho also regulates cytoskeletal organization. PI3K signaling has 
been linked to a number of cellular processes (Adjei, 2001; Rowinsky et al., 1999)
(Figure 4). Ras activation leads to enhanced signal transduction pathways that mediate 
the cell cycle, and plays a role in the proliferation of cells. It also leads to the activation 
of other types o f signals ranging from upstream of receptor tyrosine kinases to a 
downstream cascade o f protein kinases. These kinases control a wide variety o f cellular 
processes including mitogenic signaling, cellular differentiation, nuclear localization, 
cytoskeleton rearrangement, and apoptosis (Adjei, 2001; Lowy and Willumsen, 1993).
Mutant oncogenic ras genes are frequent genetic aberrations found in 20% to 30% 
of all human tumors, although the incidences by tumor type vary greatly. The highest 
incidence o f Ras mutations was detected in adenocarcinomas o f the pancreas, the colon, 
and the lung (Reuter et al., 2000). Mutated ras oncogenes were first identified by their 
ability to transform NIH 3T3 cells after DNA transfection. Subsequent analysis of a 
variety o f tumor samples revealed that in each tumor, one of the three ras genes harbored 
a point mutation (Rowinsky et al., 1999) (Table 2). Mutation o f K-ras is most commonly 
found in human tumors, whereas N-ras mutations are encountered less often and H-ra.v 
mutations are encountered rarely (Oliff, 1999). Mutations of the K-ras gene are found 
exclusively in colon, lung, and pancreatic cancers. In cancers o f the kidney, bladder, and















A n ti-a p o p to sis
JUK
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C ytosk eleta l
organ ization
Proliferation
Figure 4 General downstream effectors o f Ras protein and their functions. (GF, growth 
factor; GEF, guanine-nucleotide-exchange factor; SOS, son-of-sevenless; GAP, GTPase 
activator; NF1, neurofibromin; MEK, mitogen-activated protein (MAP) kinase kinase; 
ERK, extracellular signal-regulated kinase; MEKK, MAP kinase kinase kinase; JUK, Jun 
amino-terminal kinase; PI3K, phosphatidylinositol-3’-kinase; Akt, protein kinase B) 
(Rowinsky et al., 1999).
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Table 2 Ras mutation in human tumors
Tumor Type Ras Mutation (%) Predominant m s  Mutation
Acute myelogenous leukemia 23-30 N
Bladder 1 0 H
Breast 2 H, K





Endometrial carcinoma 18-40 K
Liver 10-30 N
Lung
Large-cell carcinoma 21-33 K
Adenocarcinoma 22-50 K
Kidney 1 0 H
Melonoma 5-15 N
Ovarian carcinoma 23 K
Pancreatic carcinoma > 80 K
Seminoma 43 K, N
Skin: keratoacanthoma 26 H
Thyroid
Follicular adenoma 28 H, K, N
Follicular carcinoma 53 H, K, N
Undifferentiated carcinoma 60 H, K, N
(H, H-ras; K, K-ras; N, N-ra.v) Data adapted from (Adjei, 2001; Beaupre and Kurzrock,
1999; Rowinsky et al., 1999).
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skin, mutations are primarily in the H-ras gene, while mutations in the N-rav gene are 
consistently found in cases of leukemia (Adjei, 2001; Beaupre and Kurzrock, 1999). 
Thyroid carcinomas are unique in having mutations in one o f the three ras genes. Most 
mutationally activated forms of ras genes identified in tumors result in disrupted guanine 
nucleotide regulation and constitutive activation o f Ras (Lowy and Willumsen, 1993; 
Rowinsky et al., 1999).
To inhibit constitutive activation o f Ras in tumors, researchers have focused on 
the inhibition of FTase. Initial approaches to FTase inhibition involved the use of general 
inhibitors o f isoprenylation. Synthesis o f famesyl groups can be blocked by HMG-CoA 
reductase inhibitors and the mevalonate pyrophosphate decarboxylase inhibitor (Adjei, 
2001). Currently, a new class o f antitumor drug has been described that targets the 
posttranslational modification o f the Ras protein crucial for its activity (Gibbs et al., 
1994). Several different FTIs (FTase inhibitors) have been identified that competitively 
inhibit FTase by distinct biochemical mechanisms and can be placed into three major 
categories. The first o f the general approaches has used design and synthesis o f FPP 
analogs that compete with the substrate FPP for FTase (Tamanoi et al., 1993). The 
second class of FTIs is designed to mimic the Ras C terminus. The CAAX portion o f Ras, 
starting at cysteine, contains all the critical determinants necessary for interaction with 
the enzyme FTase (Moores et al., 1991). The final class of drugs combines the properties 
of the peptidomimetics and the famesyl pyrophosphate analogs, and has therefore been 
termed bisubstrate inhibitor analogs (Manne et al., 1995).
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Ras protein is one of the primary target proteins o f chemotherapy. It ordinarily 
behaves as a relay switch within the signal pathway that tells the cell to divide. It does 
this in response to external stimuli and results in activation o f the signaling pathway. 
Activation o f the ras protooncogene plays a role in the formation of cancers in the 
pancreas, the lung, and the colon (Bos, 1989). Even though there is some evidence to 
suggest that this oncogene influences the differentiation and proliferation o f normal cells, 
as well as apoptotic processes, its precise role in malignancy is still unclear (Darley et al.,
1997). Ras has already been implicated in cell-signaling pathways of apoptosis, induced 
by various stimuli such as TNF-a (tumor necrosis factor-a), FAS, viral infection, and 
mechanical stress. Activation of Ras depends on both the inducer and the cell type; it will 
either inhibit or promote apoptosis (Billadeau et al., 1995; Gulbins et al., 1996; Trent et 
al., 1996).
2. ARGLABIN-DMA
Sesquiterpenes are the largest class o f terpenoids, and their structures are more 
diverse than any other class of terpenes. They are a widespread group o f substances 
occurring in various plant species. Many sesquiterpene lactones have already been 
identified from the family Compositae, in particular Genera Ixeris, Lactuca, Artemisia, 
and Cicholium (Chung, 2001). The therapeutic properties o f the Artemisia species, 
belonging to the Asteraceae family, are well known in the traditional pharmacopoeia of 
Europe, North America, and Asia (Klayman et al., 1984; Norvaretti and Lemordant, 
1990).
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Sesquiterpene lactones inhibit a large number of enzymes involved in key 
biological processes such as DNA and RNA synthesis, purine systhesis, glycolysis, the 
citric acid cycle and the mitochondrial electron transport chain (Beekman et al., 1997; 
Page et al., 1987). They have been extensively used due to their wide variety o f 
biological applications, which include: treatment o f migraines and inflammation; 
cytotoxic and/or antitumor activities; shared the antibiotic property to act as phytotoxins, 
mammalian toxins, and insect-feeding deterrents; and also their ability to cause allergic 
contact dermatitis (Wen et al., 2002). The cytotoxic and antitumor effects of 
sesquiterpene lactones have not been well studied due to their low potency. Recently it 
has been reported that some sesquiterpene lactones inhibit the in vitro growth o f tumor 
cells in a cytostatic fashion, and it has been proposed that if  their selectively cytotoxic or 
cytostatic actions against tumor cells can be established, sesquiterpene lactones may 
represent a new class of cancer chemotherapeutic drugs (Ross et al., 1999).
Arglabin [ 1(R), 10(S)-epoxy-5(S), 6 (S), 7(S)-guaia-3(4), ll(13)-dien-6,12-olide] 
(Figure 5), a sesquiterpene y-lactone, was isolated in the early 1980s from the aerial part 
o f the plant, Artemisia glabella, a species of wormwood endemic to the Karaganda 
region of Kazakhstan (Shaikenov et al., 1998; Shaikenov et al., 2001). The monoterpene 
limonene blocks cellular protein prenylation and causes the differentiation o f tumor cells 
(Crowell et al., 1991, Haag et al., 1992). Arteminolode, a sesquiterpene lactone from 
Artemisia rulvatica, showed selective inhibitory activity against rat FTase (Lee et al.,
1998). Therefore, the structural similarity with cellular isoprenoids makes natural 
terpenoids attractive for development o f inhibitors of protein prenylation, in particular,











Figure 5 Structure of Arglabin and Arglabin-DMA. The sequiterpene y-lactone 
Arglabin, which isl(R), 10(S)-epoxy-5(S), 6 (S), 7(S)-guaia-3(4), 1 l(13)-dien-6, 12-olide 
(A), and water soluble dimethylaminohydrochloride derivative o f Arglabin (Arglabin- 
DMA) (B) (Shaikenov et al., 2001).
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inhibition o f FTase and the oncogenic activation or the Ras protein (Shaikenov et al.,
1999). Arglabin is a derivative o f famesyl pyrophosphate, which is a substrate for FTase, 
and has structural similarity with cellular polyprenols (Epstein et al., 1991). Initial 
investigations focused on the ability o f Arglabin to inhibit polyprenylation o f cellular 
proteins because sesquiterpenes are made from farnesyl pyrophosphate (Shaikenov et al., 
1998).
The natural plant compound Arglabin is transformed by phosphorylation within 
cells, and this phosphoryiated derivative can prevent famesylation o f Ras proteins, 
arresting cell proliferation. The mechanism of action o f this new antitumor compound, 
Arglabin, suggests that some of the plant sesquiterpenes may be useful for anticancer 
therapy. Arglabin inhibits famesylation without influencing the geranylgeranylation of 
cellular proteins. The mechanism of inhibition o f the FTase reaction may be due to 
competition between farnesyl pyrophosphate and a phosphoryiated derivative o f Arglabin, 
affecting famesyl at the C-terminal cystein residue o f the Ras proteins (Shaikenov et al., 
1998).
Arglabin is registered and approved for usage in clinics in the Republic of 
Kazakhstan as an antitumor medicine. The results o f laboratory and preclinical studies 
have supported this usage by showing its high antitumor activity against malignant 
tumors. Importantly, the results o f clinical trials found the preparation is non-toxic for the 
liver and the kidneys. Also, as a result o f treatment, it has been reported that there was a
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definitive change in the cancerous activities o f hepatocellular cancer and tumors o f the 
lungs, breast and ovaries. The patients with liver cancer exhibited rapid reduction in the 
size o f tumors. There was general overall improvement of patient’s condition and 
biochemical indices, blood tests, and immune status all improved. The tumors were 
slightly reduced in size and then stopped growing. The ovarian cancer patients reported 
no accumulation o f ascetic fluid, and tumors were reduced by 30-40% of their original 
size prior to treatment. The preparation had no suppressive effect on hematopoiesis, no 
side effects, and appeared to normalize the functions of the immune system. Also, this 
drug did not affect the arterial pressure or other important functions o f cardiovascular 
system (Institute o f phytochemistry catalog, 2 0 0 0 ).
Arglabin is a colorless crystalline compound isolated from A. glabella, 
chromatographically purified, and then recrystallized. In general, this compound is not 
water soluble and does not exhibit potent cytotoxicity. To overcome these limitations, the 
compound has been modified to render it water-soluble through the addition o f a 
dimethylaminohydrochloride group to the C 13 carbohydride moiety, yielding Arglabin- 
DMA (Figure 5). This renders it more effective against tumors at lower concentration. 
Arglabin-DMA is phosphoryiated intracellularly. This complex inhibits the famesylation 
of Ras protein by competing with famesyl diphosphate and inhibits cell proliferation o f a 
variety o f tumor types (Shaikenov et al., 2001).
The mutation o f ras genes may affect alternative mechanisms o f activation in 
tumor cells. The screening o f natural compounds and the design o f chemical molecules
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therefore target the posttranslational modification of the Ras protein. Some of these 
compounds inhibit the enzyme FTase which is required for Ras to associate with the 
plasma membrane (Ouintero et al., 1999). Arglabin, as a biosynthetic derivative o f the 
famesyl pyrophosphate, has a similar chemical structure to the famesyl moiety o f Ras 
proteins. Arglabin inhibition of cell growth may be mediated by its phosphoryiated 
metabolites in the cells. The action mechanism of the new antitumor compound, Arglabin, 
suggests that some of the plant sesquiterpenes may be useful for anticancer therapy 
(Shaikenov, 1997; Shaikenov et al., 1998).
3. APOPTOSIS
Birth and death are the two extremes o f life. A balance between birth and death 
regulates cell numbers, relating proliferation, growth arrest, and cell death. A single 
ovum after fertilization (zygote) is capable o f dividing and giving rise to a fully grown 
individual whose normal somatic cells are programmed to die after aging (i.e. 
programmed cell death (PCD) or apoptosis). Normal somatic cells are programmed to die 
(or undergo apoptosis); on the other hand, cancer cells program themselves to survive 
(Michaelson, 1991; Vermes and Haanen, 1994).
Cancer cells can be considered as a disturbance in the relative rates o f cell 
proliferation and cell death. Cancer cells, whose origins are from a group o f normal 
somatic cells, have many characteristics in common with those cells. Somatic cells
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undergo aging and die, however, cancer cells also undergo cellular aging but are able to 
survive, sometimes achieving immortality (Michaelson, 1991). Some mutated genes 
responsible for production of growth factors and their receptors, misdirected signal 
transduction pathways, and many cell-cycle regulatory genes have been implicated in this 
process o f cancerous transformation (Hanahan and Weinberg, 2000; Lundberg and 
Weinberg, 1999; Nowell, 1990).
Traditionally, more attention has been paid to aspects of cell proliferation rather 
than to cell death. There are two major way in which cells die: necrosis and apoptosis. 
Necrosis is a pathological death (an uncontrolled cell death), characterized by cell 
swelling, mitochondrial damage, a breakdown of homeostatic control, cell membrane 
lysis, aspecific DNA degradation, and leakage o f cell content, etc. Necrotic cells cause 
inflammatory reactions in adjacent tissues. However, apoptosis, physiological death, is a 
genetically encoded cell elimination program that controls cell numbers and organ size 
(Figure 6 ). Although apoptosis as a form of cell death has been recognized for a long 
time, its relevance to cancer has been appreciated only in recent years. Indeed, cells with 
DNA damage, which escape the DNA repair mechanisms, are committed to suicide. This 
mechanism attempts to prevent the inheritance of DNA mutations in the potential 
progeny of sublethally damaged cells. Cells from a wide variety o f malignancies show a 
decreased ability to undergo apoptosis in response to physiological stimuli (Nowell, 
1990).
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Figure 6 Main differences between apoptosis and necrosis (Michaelson, 1991; Tomei 
and Cope, 1991).
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In all self-renewing tissues and cells, reproduction through mitosis is 
counterbalanced by cell removal through apoptosis. Cells dying by apoptosis usually 
undergo characteristic morphological and biochemical changes. Apoptosis, an orderly 
and genetically controlled form of cell death, concludes with phagocytosis of cellular 
remnants without causing damage such as inflammatory reactions to adjacent tissues. 
Apoptotic cells undergo separation from their neighbors by morphological, biological, 
and molecular changes. The types o f morphological change consist o f membrane 
blebbing, chromatin condensation, nuclear breakdown into micronuclei, and cytolysis 
into condensed apoptotic bodies. The types o f biological and molecular changes include 
BCL-2/BAX interactions, loss o f mitochondrial membrane potentials, phosphatidylserine 
extemalization, DNA denaturation and cleavage (50-300kb) among others. Apoptosis is 
an important feature that allows the organism to eliminate DNA-damaged cells, and 
prevents survival of suboptimal cells in tissues which may otherwise lead to the 
propagation of damaged DNA to daughter cells (Hanada et al., 1993; Rechavi et al., 1989; 
Vermes and Haanen, 1994).
One o f the first organisms in which suicide genes were identified was 
Caenorhabditis elegans, a nematode. Two death genes, ced-3 and ced-4, and an anti­
death gene, ced-9, have been identified in C. elegans. In mammalian cells, a cancer- 
causing oncogene, bcl-2, which is an anti-suicide gene similar to ced-9 o f C. elegans, is 
23% identical in sequence. Bcl-2 was shown to prevent lymphocytes from committing 
suicide and to block apoptosis. Recently, the ced-3 gene o f roundworm, which plays a 
role in apoptosis, was shown to have sequence homology with a mammalian gene, “ICE”.
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This gene encodes a cysteine protease involved in the processing o f interleukin-lb and 
acts as an interleukin-lb-converting enzyme (ICE) (Stewart, 1994; White, 1993). 
Therefore, the C. elegans model has been valuable in the identification o f the proteins 
that control apoptosis in human cells (Wickremasighe and Hoffbrand, 1999).
The process o f apoptosis is dependent on the activities of a family o f proteases 
known as caspases (Alnemri et al., 1996). Caspases exist as inactive zymogens in all 
animal cells (Nagata, 1997). The activities o f these proteases are governed directly or 
indirectly by a variety of other proteins that either promote or inhibit apoptosis. The final 
step of apoptosis induction, termed ‘execution’, involves proteases o f the ICE family, 
which directly causes destruction of the cell (Martin and Green, 1995). Members o f a 
family o f proteases, the cysteine proteases, have an active site with a conserved amino 
acid sequence allowing them to cleave proteins following aspartate residues. These 
proteases play a direct role in the hydrolytic digestion of the cell. They have been dubbed 
caspases (cysteine-dependent aspartate cleaving protease) due to their shared structural 
and functional features. Caspase-1 was the first member to be identified as a protease 
involved in mammalian apoptosis, due to its homology with CED-3 (White, 1993; Yuan 
et al., 1993). To date, ten members of this family have been identified by structure and 
substrate specificity in mammalian models. It is now generally accepted that the proteins 
involved in the execution of apoptosis belong to the caspase family. The caspases can be 
activated to induce apoptosis under a variety o f conditions which include receptor-ligand 
coupled signal transduction, DNA damage, lack o f growth factors, oxidative stress, and 
breakage o f cell-cell and cell-matrix interactions.
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When cells undergo apoptosis, they generally follow one of two major pathways. 
Though they share some mechanisms, these two pathways can be separated into an 
extrinsic pathway, and an intrinsic pathway. In some cases, extrinsic signals such as 
death receptor ligands (cytokines) are the apoptotic stimuli. This is also called the death 
receptor pathway. Such a mechanism is best illustrated by the tumor necrosis factor 
receptor (TNFR) family members, such as Fas (CD95, specific for the Fas ligand) and 
TNFR1 (which binds TNF). Upon its activation, Fas recruits FADD (Fas-associated 
death domain) by interaction of their respective death domains (DDs). Similarly, TRADD 
(TNFR 1-associated death domain protein) binds to TNFR1 and connects it to FADD via 
interaction between these domains. Subsequently, FADD activates FLICE (FADD-like 
ICE, caspase), inducing the apoptotic execution which is the final stage o f apoptosis. The 
procaspase recruited by death domain is immediately cleaved to produce the initiation 
caspase (caspase 8 ) (Green, 1998; Nagata, 1997). In the second type o f death pathway, 
intrinsic signals such as damage caused by radiations and chemicals induce apoptosis in 
p53-dependent manner (Bennett, 1999). This is also called the intrinsic pathway or drug- 
induced pathway o f apoptosis. The mitochondria and caspase apoptotic pathways are 
intimately connected (Sellers and Fisher, 1999). One of the proapoptotic factors released 
from mitochondria during apoptosis is cytochrome c. In the cytosol, cytochrome c binds 
the adapter protein Apaf-1 and, in the presence of ATP/dATP, it promotes the assembly 
of a multiprotein complex called the apoptosome which, in turn, binds and activates 
procaspase-9 (Ferraro et al., 2003). The apoptosome is the executioner o f the intrinsic 
pathway.
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The second apoptotic pathway is likely regulated by the Bcl-2 family o f proteins. 
The Bcl-2 family consists o f proapoptotic factors such as Bax, Bak, Bcl-Xs, Bid, and Bad, 
and antiapoptotic factors such as Bcl-2, Bc1-Xl, and Bcl-W. Proapoptotic Bcl-2 family 
members tmaslocate to and alter the permeability o f the mitochondrial membrane. The 
proapoptotic factors activate to release cytochrome c. Bcl- 2  and Bc1-Xl however act to 
prevent cytochrome c release and thus interfere with this caspase pathway (Green, 1998). 
The caspases are influenced by association o f two different factors in Bcl-2 family such 
as Bax-Bax homodimer functions in active apoptosis. Also, the process can be opposed 
by heterodimerization of Bax with Bcl-2 (Bax-Bcl-2). This association blocks caspase 
activity and therefore allows for cell survival. It has been suggested that the ratio o f Bcl-2 
to Bax determines survival or death following an apoptotic stimulus (Hoffman and 
Liebermann, 1994; Oltvai et al., 1993; Yang and Korsmeyer, 1996).
Recently, Bid, one o f the Bcl-2 family, was found to be a very important 
mechanism for cross-talk between the apoptotic pathways. Inefficient activation of 
caspase- 8  under the extrinsic pathway cleaves Bid, producing a C-terminal fragment. 
Activated Bid binds to mitochondria and induces release o f cytochrome c, causing the 
formation of the apoptosome in the intrinsic pathway. The initiation caspases (caspase-8 , 
-9) activate execution caspases such as caspase-3, -6 , and -7. These execution caspases 
cleave relevant substrates that induce the biochemical and morphologic characteristics of 
apoptotic cells (Pruschy et al., 2001) (Figure 7).
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Figure 7 Three major apoptosis pathways. The first pathway, the intrinsic pathway, is 
represented by the death receptor. The second, the extrinsic pathway, is represented by 
the radiation and chemicals. The third pathway is a mechanism for cross-talk between the 
apoptosis pathways; in a weak caspase 8  o f the extrinsic pathway, activates Bid mediate 
to release cytochrome c thus entering the intrinsic pathway. (Pruschy et al., 2001;
Schuler and Green, 2001).
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Oncogenes and tumor suppressor genes control the balance between apoptotic 
death and antiapoptotic survival signals, which determine whether a cell proliferates or 
dies. Changes in products o f oncogene or tumor suppressor genes can be responsible for 
initiation of apoptosis (Leblanc et al., 1999). The c-myc oncogene, which is known to be 
important for control of cell proliferation, plays a part in the regulation of apoptosis. Ras 
activation o f PI3K suppresses c-Myc-induced apoptosis through the activation of 
PKB/Akt (Kauffmann-Zef et al., 1997). Removal of activated Ras in tumor cells initiates 
apoptosis that is dependent on c-Myc activity. Apoptosis is also initiated by an inhibitor 
o f MEK (MAPK/ERK kinase), a kinase downstream of Ras (Tsuneoka and Mekada,
2000). Ras-mediated signals, that inhibit apoptotic cell death, were shown to act through 
PI3-kinase and AKT pathways, both leading to a block of cytochrome c release from the 
mitochondrial outer membrane (Kennedy et al., 1999). The tumor suppressor gene, p53, 
has been shown to have dramatic effects on apoptosis. Its gene product, p53, can delay 
cell cycle progression before initiation o f DNA replication by arresting this cycle 
following DNA damage (Slichenmyer et al., 1993). The putative oncogene bcl-2 is 
considered to be an apoptosis suppressor gene. Multiple genetic events are associated 
with tumor development. Among those events are the activation of bcl-2, and the 
inactivation o f apoptotic inducers such as p53 and bax (Chiou et al., 1994).
Cell death can also be induced by hormonal signals (prostaglandin E, adenosine) 
to the membrane. cAkinase (cAMP-dependent kinase) has been implicated in the nuclear 
response to hormonal signals for cell proliferation, differentiation, and apoptosis. 
Apoptosis is induced by agents that increase cAMP (eg. cholera toxin, theophyline,
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Isobutylmethylxaminthine) and cAkinase agonists (eg. cAMP analogues). Blocking gene 
expression and/or protein synthesis can prevent cAMP-induced apoptosis. ICER 
(inducible cAMP early repressor) represses cAMP-induced cell death. This indicates that 
cell death was induced by transcriptional activation of a ‘killer’ gene regulated by a CRE- 
containing promoter. ICER and Bcl-2 both act as upstream and downstream switches 
respectively, and may decide the fate o f the cell (Raghoebier et al., 1991; Rechavi et al., 
1989).
Many chemotherapeutic agents of diverse origin and different primary target 
molecules may induce apoptotic cell death in cancer cells via a convergence of 
intracellular pathways. Thus, the identification o f impediments to this pathway, whether 
of genetic origin (e.g. bcl-2) or by interacting cytokines or factors as yet unknown, are 
important in identifying potential causes of drug resistance in malignant cells (Allen et al., 
1993).
Recent data show that in some cellular models, chemotherapeutic agents induce 
apoptosis, an irreversible process which leads to a rapid and complete elimination of 
tumor cells. However, further studies also demonstrated that apoptosis, induced by 
anticancer agents, is highly regulated by multiple signaling pathways which are 
themselves influenced by oncogenes, protein kinase/phosphatase activities, external 
stimuli, and the oxidative balance. Often, they share the same signaling pathways with 
cell proliferation and differentiation (Ruchaud and Lanotte, 1997). Therefore, it appears 
that cell death commitment is controlled by both external and internal factors which
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
31
interfere with the downstream of drug-target interactions. The characterization of these 
factors may provide novel targets for modulating drug-activated intracellular signaling 
pathways in order to promote apoptosis in drug-resistant cells (Allen et al., 1993; Sellers 
and Fisher, 1999).
Two major cellular effects o f FTI are cell cycle effects and induction o f apoptosis. 
The FTI-induced apoptosis involves changes in mitochondrial membrane potential and 
the release o f cytochrome c. The released cytochrome c activates caspase-9 and caspase-3, 
leading to DNA fragmentation. Detection of FTI-induced apoptosis requires special 
conditions, such as exposing cells to low serum conditions to inhibit cells from attaching 
to extracellular matrix (Edamatsu et al., 2000; Lebowitz et al., 1997; Suzuki et al., 1998).
4. CELL CYCLE
The cell cycle consists o f four sequential stages. Gi is the first gap phase in which 
cells prepare for DNA replication. In this phase, cells monitor both their internal and 
external environments to determine whether to divide or to remain in a state of 
quiescence, known as Go. In Go, basic cellular metabolism is depressed in general, 
including transcription and transition. Once initiated, the cell progresses from the Gi to S 
phase, the period of DNA synthesis for the reproduction o f the whole genome. Then, the 
cell progresses to the G2 phase, the second gap phase in which cells prepare for mitosis, 
before entering into M phase. M phase, or mitosis, is the period of cell division in which 
two identical daughter cells are produced during prophase, prometaphase, metaphase,
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anaphase, and telophase. Cells can exit the cell cycle to settle into the Go phase in 
response to the deprivation of nutrients and growth factor stimulation (Brooks and La 
Thangue, 1999; Owa et al., 2001).
As cells enter the cycle from Go/Gi,one or more D-type cyclins (D l, D2, and D3) 
are expressed as part o f the delayed early response to mitogen stimulation. Progression 
through the Gi phase initially depends on holoenzymes composed of one or more o f the 
D-type cyclins (D l, D2, and/or D3) in association with cyclin-dependent kinases (CDKs), 
CDK 4 or CDK 6 . The CDKs are protein complexes that are composed o f a regulatory 
cyclin subunit and a catalytic partner. This is followed by activation o f cyclin E-CDK 2 
complex as cells approach the Gi/S transition. Together, cyclin E and CDK 2 act to 
hyperphosphorylate retinoblastoma protein (pRb), which then releases the elongation 
factor E2F that activates DNA polymerase. This step, termed the restriction point, 
represents the point of no return; cell commitment to undergo DNA synthesis (S phase) 
and mitosis is inevitable. In the S/G2 transition and G2 phase, cyclin A binds CDK 2 and 
CDC 2, giving two distinct cyclin A kinase activities, one appearing in S phase, the other 
in G2  (Pagano et al., 1992). The G2 /M transition is mediated by activation o f the cyclin 
B/CDC 2 kinase complex (Figure 8 ). At each phase of cell cycle, the scheduled activity 
o f the CDKs is controlled by their association with cyclins and the CDK inhibitors 
(CKIs). CKI molecules are categorized into two separate families: 7) INK 4 family 
(p l 6 INK4a, p l5 INK4b, p l 8 INIC4c, and p l9 INK4d) specifically inhibit the catalytic subunits of 
CDK 4 and CDK 6 ; and 2) Cip/Kip family (p21Cipl, p27Kipl, and p57Kip2) inhibit the 
activities of cyclin D-, E-, and A-dependent kinases (Ammit and Panettieri, 2001; Sherr
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Figure 8 The cell cycle. The normal cell division cycle is sub-divided into four distinct 
phases: two gap phase (GI and G2), S phase and M phase. CDK; cycling-dependent 
kinase, CDC 2; cell-division cycle, one o f the CDKs (Brooks and La Thangue, 1999).
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and Roberts, 1999). Each phase of the cycle is under the control o f specific positive and 
negative regulators that either promote or arrest cell-cycle progression depending on their 
relative levels o f expression (Brooks and La Thangue, 1999; Shapiro and Harper, 1999).
Proliferative disorders such as cancers are recognized as diseases of the cell cycle. 
The disorders are found in genetic alterations affecting proteins that control cell cycle 
progression. The mechanisms that normally function to restrain cell division are defective, 
while those that promote division become more active. The genes responsible for these 
changes in growth potential are generally named tumor suppressors and oncogenes, 
respectively (Brooks and La Thangue, 1999; Wang et al., 1996).
Ras proteins are encoded from the proto-oncogene ras, and are involved in cell 
signaling and regulation of cell proliferation. Activated Ras interacts with a diverse 
spectrum of effectors, initiating a multitude o f cytoplasmic signaling cascades. Recent 
studies have begun to establish the links between Ras signaling pathways and cell cycle 
regulatory proteins. The mechanism by which aberrant Ras and Rho GTPase activation 
promotes oncogenesis clearly involves a deregulation of cell cycle progression. Much is 
now known regarding how Ras and Rho signaling can control both positive and negative 
regulators to facilitate an exit from Go, progression through Gi, and initiation o f DNA 
synthesis (Bar-Sagi and Hall, 2000). Raf signal, activated by Ras, can induce cyclin Dl 
expression, allowing cyclin D l to complex with Cdk4 and Cdk6 and phosphorylate Rb to 
affect the GI to S transition. Rho activates CDK 2 and also inhibits p21Cipl and p27K'pl to 
induce cyclin D l and stimulate the GI to S transition. Rho represses p21Cipl expression to
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block p21Cipl induction by Ras and to allow Ras induced progression from GI to S 
(Liberto et al., 2002). Also, Rac, one o f the Rho family members appears to induce cyclin 
D l expression and induce the GI to S transition primarily through activation o f NF-kB to 
activate the cyclin D l promoter. The cooperative action of Ras, Rac and Rho to induce 
cyclin D l expression is a key component of oncogenic transformation (Chang et al.,
2003; Pruitt and Der, 2001).
Recent excitement in cancer research concerns the development o f a new 
generation o f antitumor drugs. These drugs are designed to target molecular events 
specific to cancer cells, including FTIs (famesyl transferase inhibitors). FTIs have been 
developed in an attempt to inhibit membrane association of Ras. While it is demonstrated 
that FTIs are effective in reverting phenotypes due to H-ras activation, a number of 
reports suggested that there are targets other than Ras that are critical for the FTI effects. 
Studies on protein famesylation define the effects o f FTIs on cancer cells with the aim of 
gaining insight into the involvement of famesylated proteins other than Ras on FTIs. 
These include members of the Ras superfamily G-proteins (Foster et al., 1996; Lebowitz 
et al., 1997; Murphy et al., 1996). One o f two major effects of FTI is the ability to cause 
changes in cell cycle progression (Jiang et al., 2001; Tamanoi et al., 2001). The cell cycle 
effect involves enrichment of either Go/Gi phase cells or G2/M phase. Characterization of 
the FTI-induced G0/G 1 enrichment led to the findings that FTI affects the expression and 
modification of a number o f cell cycle related proteins. With some cell lines, G2 /M 
enrichment was detected after the treatment with FTI (Jiang et al., 2001).
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5. PURPOSE OF THIS STUDY
Many chemotherapeutic agents induce cell death in tumor cells via a convergence 
o f intracellular pathways, which lead to apoptosis. After chemotherapy, the balance 
between the relative rates o f cell proliferation and cell death is related to the regulation of 
apoptosis or the cell cycle. In previous studies, the major cellular effects of FTase 
inhibitors (FTIs) were cell cycle effects or induction of apoptosis. Arglabin-DMA has 
been shown to be a potent inhibitor o f tumor growth. It may inhibit FTase as the 
chemotherapeutic target. However, the mechanisms by which Arglabin-DMA inhibits 
tumor growth in vivo and in vitro are still relatively unknown. To elucidate this 
mechanism, we hypothesize that Arglabin-DMA has major cellular effects similar to 
those o f other FTIs to inhibit tumor growth.
The present study addresses the effects of Arglabin-DMA in vitro, using a 
cultured cell model to confirm or refute its proposed role as a Ras-dependent FTI. To 
determine the mechanism by which this drug inhibits tumor growth, the effects of 
Arglabin-DMA are examined in human colon tumor cells. Experimentation is divided 
into three specific aims: In the first specific aim, we re-examine the ability o f Arglabin- 
DMA to inhibit Ras activity in vitro. The second examines whether Arglabin-DMA 
inhibits cancer growth in an apoptosis-dependent manner. Finally, we determine that 
Arglabin-DMA induces cell cycle arrest in human colon tumor cell lines.
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5.1. Reexamination of the ability of Arglabin-DMA to inhibit farnesylation on the 
Ras protein in vitro
Viability assays are principally used to enumerate the proportion o f living and 
dead cells in a population. Trypan blue is generally used for the viability assay. The 
reactivity o f trypan blue is based on the fact that the chromopore is negatively charged 
and does not enter the cell unless the membrane is damaged. This stain is actively 
extruded from viable cells, but readily enters and stains dead cells. Using viability assays, 
the viable population percentage between groups, which have been exposed for varying 
times or concentrations of the drug, is compared. These comparisons are used to 
determine the effectiveness o f the drug action.
In today's pharmaceutical industry, most o f the new anticancer drug candidates 
fail clinical trials due to their toxicity, even though they significantly inhibit tumor cell 
growth rate. These high failure rates may be reduced if potential drugs are screened for 
toxicity earlier in the drug discovery process. Evaluation o f toxic effects of potential 
drugs is cost effective in an in vitro system using cultured cell lines or primary cells. Also, 
cytotoxicity studies are used to predict drug metabolism pathways in humans. To 
compare the effects of Arglabin-DMA in a normal human cell line and colon tumor cell 
lines for toxicity, several positive controls (5-Fluorouracil, Lovastatin, or Taxol) were 
used.
Previous studies showed that Arglabin-DMA inhibits polyprenylation of the 
cellular proteins, presumably because plant sesquiterpenes function as polyprenols of
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cellular proteins. Arglabin can inhibit famesylation without influencing 
geranylgeranylation (Shaikenov et al., 1998). We attempted to reconfirm that Arglabin- 
DMA inhibits polyprenylation and the formation o f isoprenoids (famesyl pyrophosphate 
and geranylgeranyl pyrophosphate) which are byproducts of cholesterol synthesis.
5.2. Test whether Arglabin-DMA inhibits cancer cell growth in an apoptosis- 
dependent manner
We examine a broad and chronologically characteristic pattern o f morphological, 
biochemical and molecular changes o f apoptosis to determine whether Arglabin-DMA 
activates apoptosis in human colon tumor cells or not. At the biochemical level of 
apoptosis, double-strand cleavages o f genomic DNA are found by conventional agarose 
gel electrophoresis and are also detected by the TUNEL assay in our experiments. 
Differences in the permeability of the cell membranes of living, dead, and apoptotic cells, 
are used to identify apoptotic cells using two DNA dyes, acridine orange (AO) and 
ethidium bromide (EB). The fine architecture o f the cell membrane changes in the initial 
phase o f apoptosis. This shift in the architecture o f the plasma membrane involves the 
redistribution of the various phospholipid species between the two leaflets o f the 
membrane. We can detect membrane conversion in apoptotic cells through the use of 
Annexin V. Finally, alterations o f the plasma membrane in apoptotic cells lead to the 
accumulation within the cell of a detectable dye.
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5.3. Testing whether Arglabin-DMA induces cell cycle arrest in human colon tumor 
cell lines
In the analysis of the mechanism of Arglabin-DMA using flow cytometry, the 
relationship of Arglabin-DMA and the cell cycle is studied in colon tumor cells. Once 
cells are stained with propidium iodide (PI) as the DNA fluorochromes, they are analyzed 
by flow cytometery. Where the relative content o f DNA indicates the distribution o f a 
population of cells throughout the cell cycle.
The aim of this last study is to compare the changes of the cell cycle after 
exposure to Arglabin-DMA. Studies using increased concentrations o f Arglabin-DMA, 
followed by examination o f cells using flow cytometry, are capable o f showing the drug’s 
concentration correlation with the inhibition o f cell progression. Also, DNA content 
frequency histograms may reveal fractional DNA content, represented by the sub-diploid 
(<2n: sub-Gi) peak. In late apoptotic cells, DNA is degraded to such an extent that it 
becomes extracted during the routine procedure o f cell staining. This approach is 
currently the most frequently used in flow cytometry to identify and quantify apoptotic 
cells (Nicoletti et al., 1991).
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MATERIALS AND METHODS
1. HUMAN CELL LINES
We investigated the effects o f Arglabin-DMA on two human colon cancer cell 
lines, each having different Ras and p53 status (HCT 116 and HT-29). HCT 116, derived 
from a colon carcinoma, contains a mutation in codon 13 of the K-ras protooncogene and 
wild-type p53. HT-29, derived from a colon adenocarcinoma, has a mutation in codon 
237 of the p53 and a wild-type ras. The normal cell line (Hs 27), used as a control for 
examining cytotoxicity, is a fibroblast. All cell lines were obtained from American Tissue 
Culture Collection (ATCC, Rockville, MD. USA).
2. DRUG EXPOSURE
Arglabin, like other sesquiterpenes, is biosynthetically derived from famesyl 
diphosphate by cyclization, rearrangements and oxidation. The water soluble form of 
Arglabin is Arglabin-dimethylaminohydrochloride (Arglabin-DMA; Figure 2). Powdered 
Arglabin-DMA was obtained from the Institute of Phytochemistry, Republic of 
Kazakhstan. It was dissolved with distilled water and presented at various final 
concentrations (15.25, 30.50, and/or 45.75 pM).
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5-Fluorouracil, Lovastatin, Mynumycin A, or Taxol were used as positive 
controls in several experiments. They were obtained from Sigma (St. Louis, MO. USA). 
5-Fluorouracil is a potent antitumor agent that affects pyrimidine synthesis by inhibiting 
thymidylate synthetase. It was dissolved in DMSO and administrated at 19.22 pM (Nita 
et al., 1998). Lovastatin (Mevinolin) is a potent inhibitor o f HMG-CoA reductase, the 
rate-limiting enzyme in cholesterol biosynthesis. Lovastatin was dissolved in methanol 
and administrated at 10 pM (Agarwal et al, 1999; Agarwal et al, 2002). Manumycin A is 
a FTI (famesyltmasferase inhibitor) in that it is FPP (famesyl pyrophosphate) analog. It 
was dissolved in methanol and administrated at 20 pM (Di Paolo et al, 2000). Taxol 
(Paclixel) is an anti-tumor agent which binds to the N-terminal region of (5-tubulin. It was 
dissolved in distilled water and administrated at 58 nM (Banerjee et al., 1997). All drugs 
were stored at over -20°C and solutions were prepared fresh for each experiment.
3. INITIATION AND MAINTENANCE OF HUMAN CELL LINES
Two colon tumor cell lines and one fibroblast line were stored at -155°C, 
according to the instructions of ATCC for use. Complete media for HCT 116 and HT-29 
was prepared using McCoy 5A medium (Sigma, St. Louis, MO. USA). Complete media 
for Hs27 was prepared with Dubecco’s modified Eagle’s medium (Sigma, St. Louis, MO. 
USA), each containing 10% fetal bovine serum (GIBCO BRL, Life Technologies, 
Gaithersburg, MD. USA), 200 mM Glutamine, 50 units/ml penicillin, and 50 mg ml"1 
streptomycin (Sigma, St. Louis, MO. USA). Cells were thawed and placed in 25 cm 
culture flasks (T-25) (Coming, Coming, NY. USA) in volumes of 5ml of complete media.
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Cells were allowed to adhere to flasks, and the flasks were placed in a 37°C incubator 
with 95% air, 5% CO2 humidified atmosphere. Cells were fed every 2 days with complete 
media after old media were discarded. The primary cultures were allowed to grow to 
subconfluence, trypsinized, and passed into 75 cm culture flasks (T-75) (Coming, 
Coming, NY. USA). Depending on the cell density, cells in a given flask were 
subcultured into two or three flasks before reaching confluence.
Under these conditions, the population doubling time of HCT 116 was about 24 
hours, that o f HT-29 was about 30 hours, and that of Hs27 was about 48 hours. Cultures 
were regularly examined under the microscope for contamination and/or confluence; if 
the culture was contaminated, we added 1 to 2 ml of bleach and disposed of cultures in an 
appropriate biohazard container. If the cells grew to confluence, they were split. Cultures 
were found to be free of Mycoplasma contamination procedure. All experiments involved 
cells that were passaged more than 30 times. All procedures were performed under a 
sterile hood utilizing sterile techniques.
4. TRYPSINIZATION AND CELL PASSAGE
Cultures were passaged and harvested using 0.05% trypsin-EDTA (Sigma, St. 
Louis, MO. USA) to detach the cells. The cells grown to confluence were prepared to be 
split. The media from flasks was removed and discarded in bleach. The flasks were rinsed 
with 3 ml o f trypsin-EDTA to remove residual media. Two ml o f trypsin-EDTA in T-25 
flasks, or 4 ml o f trypsin-EDTA in T-75 flasks were added. The flasks were placed in the
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incubator at 37°C. Trypsinization was periodically observed under the light microscope, 
as various cell types detach at different rates (trypsinization is typically complete within 3 
to 10 minutes). When most of the cells had become “rounded” (i.e., when the trypsin had 
disrupted the cells’ protein connection to the flask surface), the flasks were tapped gently 
on each side to dislodge the attached cells into suspension. Each flask was neutralized 
with complete media, using the same as the amount o f trypsin-EDTA. The cells and 
media were triturated to obtain a homogenous suspension. The cell suspension o f colon 
tumor cell lines was aliquoted in 1 ml volumes into new sterile T-25 flasks or aliquoted in 
3 ml volumes into new sterile T-75 flasks. The cell suspension of Hs 27 (normal cell line) 
was aliquoted in 2 ml volumes into new sterile T-25 flasks (5 ml total volume) or 
aliquoted 6 ml volumes in to new sterile T-75 flasks (15 ml final volume).
5. CELL COUNTING AND CELL VIABILITY
Cells were plated in T-25 at a density o f 2 * 104 cells per cm2. After incubation 
for 24 hours, old media were discarded. This step was done to insure that more precise 
data would be obtained, due to the fact that Arglabin-DMA induces cell rounding and 
detachment. Complete media containing Arglabin-DMA were added to the flasks at 
various final concentrations (0, 15.25, 30.50, and 45.75 pM). 5-Fluorouracil (19.22 pM); 
Lovastatin (10 pM); or Taxol (58 nM) was used, separately as positive controls, and 
compared to the growth inhibition rate of Arglabin-DMA. Detached and attached cells in 
control and drug exposure samples were collected by trypsinization at different times (24, 
48, and 72 hours) o f incubation. As in the previously described trypsinization, the cells
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and media were triturated to a homogenous suspension. 300 pi o f the suspension was 
diluted 1:1 with pipette into 300 pi o f 0.4% trypan blue solution (Sigma, St. Louis, MO. 
USA) into a disposable culture tube. The diluted suspension was mixed to the disposable 
culture tube containing the cell suspension. One drop from the disposable culture tube 
was pipetted into the hemacytometer and allowed to stand for 5 minutes.
The viable cells appear clear and round with no blue-colored dye; the blue-dyed, 
non-viable cells were counted in the four comer square chambers o f the grid o f a 
hemacytometer. Use o f a hemacytometer is critical for obtaining an accurate count of 
cells. The cell count was calculated using the equation: cells/ml = (n) x 104, where: n = 
the average cell count per square o f the four comer square chamber counted. We 
determined the total number of cells in the total suspension volume. The percent viability 
o f cells in culture was calculated. The cellular morphologies o f human cell lines in 
various assays were examined under Olympus phase light microscope (Tokyo, Japan) at 
100 x magnification. Light photomicrographs (ISO 200 and 400) were taken with an 
Olympus camera (Tokyo, Japan).
6. ADD-BACK EXPERIMENTS
To evaluate the cellular mechanisms involved in Arglabin-DMA growth 
inhibition, add-back experiments were performed, adding intermediates (farnesyl 
pyrophosphate (FPP), or geranylgeranyl pyrophosphate (GGPP)) in cholesterol 
biosynthesis which belong to a class o f molecules called isoprenoids (Holstein et al.,
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2002). Isoprenoids are attached to several cellular proteins, including G proteins, by a 
posttranslational modification termed isoprenylation (Agarwal et al., 1999). Lovastatin, 
which served as a positive control, induces morphological changes (cell-rounding and 
detachment) similar to Arglabin-DMA-induced cell-rounding and detachment. It is an 
HMG-CoA reductase inhibitor. Inhibition of HMG-CoA reductase inhibits the formation 
o f isoprenoids and thereby impairs the post-translational processing o f Ras and Ras- 
related proteins (Rap la, RhoA, and RhoB). Isoprenylation of target proteins, like the 
GTP-binding protein Ras, is essential for their membrane localization (Agarwal et al., 
2002). Manumycin A, a second positive control, is a natural product derived from the 
bacterium Streptomyces, and is a FPP analog similar to Arglabin-DMA. It acts by the 
specific inhibition o f the FTase and exerts antiproliferative effects on human tumor cells 
which harbor a mutated K-ras gene (Di Paolo et al., 2000).
HCT 116 or HT-29 cells were seeded at 2 x 104 cells per cm2 on T-25 flask, 
permitted to attach and grow for 24 hours. We discarded the old media and divided the 
cells into two groups after adding 30 pM Lovastatin, 61 pM Arglabin-DMA, or 20 pM 
Manumycin A, dissolved in fresh, complete media. 100 pM Famesyl pyrophosphate 
(Sigma, St. Louis, MO. USA), or 10 pM geranylgeranyl pyrophosphate (Sigma, St. Louis, 
MO. USA) was then added. The samples were incubated for 3 days and photographs 
were taken after 1 and 3 days incubation for comparing the morphological appearances of 
the samples. 1 x 106 cells o f each sample were collected. We followed the experimental 
procedures for cell viability for counting cells and also checked the change in the number 
o f the floating cells, related to apoptotic cells. Higher doses o f Lovastatin (30 pM),
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Manumycin A (20 pM), and Arglabin-DMA (61 pM) were used in these experiments to 
clarify the inhibiting potential effect o f these drugs.
7. ANNEXIN V ASSAY
HCT 116 or HT-29 cells were seeded at 2 xlO4 cells per cm2 in T-25 flask and 
incubated for 24 hours. We discarded the old media and added three final concentrations 
of Arglabin-DMA (0, 15.25, 30.50 and 45.75 pM) dissolved in fresh, complete media. 
After three days of incubation, each cell line was split into three separate groups (control, 
attached in Arglabin-DMA treatment, and floating in Arglabin-DMA treatment). The 
following steps were followed using the ApoAlert Annexin V protocol (Clontech, Palo 
Alto, CA. USA). At each time point, 1 xlO6 cells o f each group were collected. The cells 
were rinsed and resuspended with 1 x Binding Buffer (0.1 M HEPES, pH 7.4; 1.4 M 
NaCl; 25 mM CaCh). 10 pi PI and 5 pi EGFP-labeled recombinant human Annexin V 
was added. For analyzing cells, the cell suspensions were incubated on a glass slide at 
room temperature for 5-15 minutes in the dark. Slides were covered with a glass 
coverslip and observed under an Olympus fluorescence microscope (Tokyo, Japan), at a 
magnification o f 200 x, using a filter set for acridine orange. Light photomicrographs 
(ISO 100) were taken with a Nikon camera (Tokyo, Japan) using 640T Tungsten chrome 
color film of Imation (Oakdale, MN. USA).
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8. APOPTOSIS DYE-UPTAKE ASSAY
A second technique to detect alterations o f the plasma membrane is the 
Apopercentage assay (Biocolor, Newtownabbey, Northern Ireland). During apoptosis, 
cells undergo the onset of the ‘flip-flop’ alteration to the cell membrane, causing 
translocation o f phosphatidylserine to the exterior surface o f the cell membrane. The 
Apopercentage Dye enters the cell following this event, and dye uptake continues until 
‘blebbing’ is induced. At this stage, no further dye can enter the cell. Once in cells, 
Apopercentage does not escape (Wilson and Elliott, 2001).
Cells o f each cell line were seeded at 2 x 104 cells per cm2 in T-25 flask and 
allowed to attach overnight. The medium was replaced with fresh media or fresh media 
containing 30.50 pM Arglabin. After exposure o f these cells to Arglabin-DMA, two cell 
lines o f different ras status, HCT 116 and HT-29, underwent the morphological changes 
causing them to round up and become detached from the substrate. In determining cell 
viability, 80-95% floating cells were live cells that did not stain with trypan-blue. For 
examining floating cells that were morphologically affected by Arglabin-DMA, we 
collected and examined cells divided into two groups (floating or attached groups) in 
each o f the colon cell lines after three days incubation. 2 x 105 attached cells or floating 
cells were collected and counted. Harvested cells were given two washes with PBS. 100 
pi aliquots of complete culture medium containing Apopercentage Dye Label were added 
and samples were incubated for 1 hour at 37°C. Cells in each group were collected and 
resuspended in 1 ml of serum-free medium. The cellular morphologies in the
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Apopercentage assay were examined. Normal cells, which appear clear, are round and 
exclude the dye; the apoptotic cells stained purple-red were counted in a hemacytometer 
under an Olympus phase light microscope (Tokyo, Japan) at a magnification of 100 x. 
Light photomicrographs (ISO 200 and 400) were taken with an Olympus camera (Tokyo, 
Japan). Total apoptotic and normal cell numbers and the percent apoptotic cells were 
calculated.
9. IDENTIFICATION OF DYING CELLS BY APOPTOTIC NUCLEAR 
MORPHOLOGY
Detection o f apoptotic cells in this experiment is based on differences in the 
permeability o f the cell membranes o f living, dead, and apoptotic cells. Two DNA dyes, 
acridine orange (AO; Sigma, St. Louis, MO. USA) and ethidium bromide (EB; Sigma, St. 
Louis, MO. USA), were used to find apoptotic cells.
HCT 116 or HT-29 cells were inoculated into 25 ml flasks with a viable cell 
density o f 2 * 104 cells/cm2. After incubation for 24 hours, old medium was discarded, 
and fresh complete media with or without 30.50 pM Arglabin-DMA was added. After 
samples were incubated for three days, cells were divided to in three groups (control, 
attaching in Arglabin-DMA treatment, and floating in Arglabin-DMA treatment) and 
trypsinized for different times for each group. Cell counts were made to determine cell 
viability and cytotoxicity.
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After counting, cells were given two washes with 1 x phosphate buffered saline 
(PBS) (0.14 M NaCl; 3 mM KC1; 10 mM Na2HPO; 2 mM KH2P 0 4, pH 7.2). Twenty-five 
microliters o f the cell suspension were mixed with 1 pi of the dye mixture containing 100 
pg/ml AO and 100 pg/ml EB in PBS (pH 7.2). EB, as a fluorescent DNA-binding dye, is 
taken up by dying cells only. Metachromatic dye AO is taken up by both live and dead 
cells. But apoptotic cells can be distinguished by their different morphologies (Reed, 
2000). After staining, cells were mounted on a hemacytometer. Cells were observed 
under an Olympus fluorescence microscope (Tokyo, Japan), at a magnification o f 200 x, 
using a filter set for AO and 640T Tungsten chrome color slide film o f Imation (Oakdale, 
MN USA). Light photomicrographs (ISO 100) were taken with a Nikon camera (Tokyo, 
Japan).
The status o f cells was identified by counting the number of cells exhibiting one 
o f five staining patterns: Stage one is bright green chromatin with organized cell 
structure-viable cells with normal nuclei. Stage two is bright green chromatin that is 
highly condensed-viable cells with apoptotic nucleic in an early phase o f apoptosis. Stage 
three is bright orange chromatin that is highly condensed-nonviable cells with apoptotic 
nuclei in a late phase o f apoptosis. Stage four is bright orange chromatin that is 
fragmented-nonviable cells with apoptotic nuclei in the late phase o f apoptosis. Stage five 
is red-dead cells (Reed, 2000).
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10. TUNEL ASSAY
The TUNEL (terminal deoxynucleotidyl transferase-(TdT)-mediated dUTP nick 
end labeling) assay was carried out using the Apoptosis Detection Kits protocol (R&D 
Systems, Minneapolis, MN. USA). The assay detects biotinylated nucleotides 
incorporated onto the free 3’-hydroxyl residues o f DNA fragments, added by Terminal 
deoxynucleotidyl transferase (TdT). Also, it inserts a deoxynucleotide-triphosphate, 
dNTP, that has a chromophore attached. The use o f this assay results in intense brown 
staining of the nuclei of apoptotic cells. Since necrotic cells may also contain DNA 
fragments that can incorporate label, the identification o f apoptotic cells can be visualized 
on a histological section by light microscopy (Reed, 2000). In this assay, attached cells 
(HCT 116 and HT-29) were exposed to Arglabin-DMA, and then monitored by the 
TUNEL assay to test the occurrence o f apoptotic events.
Sample preparation: Microscope slides and glass coverslips were sterilized by 
autoclaving for 20-30 minutes with or without pretreatment with poly-L-lysine or 
collagen to assist in cell adhesion. The sterile slides were transferred into a tissue culture 
dish. 2 x 104 cells/cm2 of HCT 116 or HT-29 were seeded in the tissue culture dish and 
allowed to attach overnight. The media were replaced with fresh media or fresh media 
containing 30.50 pM Arglabin. After 72 hours o f incubation, the media were removed 
from the dish and the slides with adherent cells were carefully rinsed with 1 * PBS (0.14 
M NaCl; 3 mM KC1; 10 mM NaiHPO; 2 mM KH2PO4, pH 7.2). The rinsed cells were
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fixed by adding 3.7 % formaldehyde solution (1 x PBS with 37% Formaldehyde) for 10 
minutes at 18-24 °C and then washed with 1 x PBS.
Labeling and detection: Each sample was permeabilized by incubation with 50 pi 
Proteinase K Working Solution (1 pi Proteinase K; 50 pi sterile water). The slides were 
incubated in a humidity chamber for 30 min at 18-24 °C and washed twice. To prepare 
the Nuclease-generated Positive Control using TACS-Nuclease, 50 pi o f TACS-Nuclease 
Working Solution (1 pi TACS-Nuclease with 50 pi TACS-Nuclease Buffer) was pipetted 
onto a no drug sample. A coverslip was placed, and the slide incubated for 10 minutes in 
a humidity chamber. The other samples were covered with TACS Nuclease buffer during 
preparation o f the Positive Control. The samples were immersed in Quenching Solution 
(30% H2 O2 with 45 ml Methanol) for 5 minutes, quenching potential high levels of 
endogenous peroxidase, and then the samples were washed for 1 minute to remove H2 O2 
solution. The samples were immersed in 1 x TdT (Terminal deoxynucleotidyl 
Transferase) Labeling Buffer (10 x Labeling Buffer) for 5 minutes. The entire specimen 
was covered with 50 pi of Labeling Reaction Mix (1 pi TdT dNTP Mix; 1 pi 50 x Mn2+; 
1 pi TdT enzyme; 50 pi 1 x TdT Labeling Buffer). To prepare an unlabeled Sample 
Control, one sample was treated with Labeling Reaction Mix from which the TdT 
enzyme had been omitted. All of the samples were placed in a humidity chamber in a 
37°C incubator for 1 hour. The reaction was stopped by immersing the samples in 1 x 
TdT Stop Buffer for 5 minutes. The samples were washed twice with 1 x PBS for 5 
minutes per wash and dried. 50 pi o f Streptavidin-HRP Working Solution (1 pi
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Streptavidin-HRP; 50 pi o f 1 x PBS) were pipetted onto each sample to cover the entire 
specimen. The samples were incubated for 10 minutes and washed twice, 2 minutes per 
wash with 1 x PBS. The samples were immersed in DAB Working Solution (30% H2 O2 ; 
250 pi diaminobenzidine; 50 pi 1 * PBS) as background staining may occur. The 
samples were washed twice in tap water for 2 minutes each wash.
Counterstaining: The samples were immersed in 1% Methyl Green Counterstain 
for 1 minute and washed sequentially by dipping in each of the following solutions: 
deionized water (2 changes, ten times each); 95% ethanol (2 changes, ten times each);
100 % ethanol (2 changes, ten times each); xylenes (2 changes, ten times each). Each 
sample was pipetted with 50 pi o f mounting medium (Permount, Williston, VT, USA) 
and grown on glass coverslips. The cellular morphologies o f human cell lines in various 
assays were examined under Olympus phase light microscope (Tokyo, Japan) at 100 x or 
200 x magnification. Light photomicrographs (ISO 200 and 400) were taken with an 
Olympus camera (Tokyo, Japan).
11. ANALYSIS OF DNA FRAGMENTATION
In apoptotic cells, DNA fragmentation is regular, in contrast to the random DNA 
degradation that occurs in necrotic cells, in that it involves the generation o f large DNA 
fragments. Apoptotic cells reflect double-strand cleavage o f linker DNA between 
nucleosomes. Large DNA fragments were found by conventional agarose gel
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electrophoresis, followed by the appearance o f a ladder of low molecular weight 
fragments that are multiphases of ~180bp (Vermes and Haanen, 1994; Reed, 2000).
In previous studies o f cell viability, exposure of cells to Arglabin-DMA caused 
them to round up and become detached from the substrate, suggesting that this compound 
may induce cells to undergo apoptosis. Therefore, three groups (control, attached in 
Arglabin-DMA treatment, and floating in Arglabin-DMA treatment) were separately 
collected. In order to detect the induction of apoptosis, DNA fragmentation, reflecting the 
endonuclease activity characteristic o f apoptosis, was detected with DNA samples 
extracted from the Arglabin-DMA treated cells at one or three days.
2 x 104 cells/cm2 per cell line (HCT 116 or HT-29) were seeded in T-75 flasks 
and allowed to attach overnight. The media were replaced with fresh media, or fresh 
media containing 30.50 pM Arglabin-DMA, 10 pM Lovastatin or 58 nM Taxol. After 1 
or 3 days of incubation, cells were collected in three groups (control, attached in 
Arglabin-DMA treatment, and unattached in Arglabin-DMA treatment), and counted. 
Harvested cells (over 3 x 106 cells) were lysed and transferred to centrifuge tubes. After 
centrifuging at 600g for 5 minutes, the supernatant was incubated with 18 pg/ml 
proteinase K overnight at 50°C. The samples were centrifuged at 2000g for 5 minutes, 
and 100 pi o f sodium perchlorate was added. The upper layer was extracted in 150 pi of 
Nucleon resin (Amersham Life Science, Buckinghamshire, UK). DNA was precipitated 
with 2 volumes of cold absolute ethanol. Precipitates were washed twice with 1 ml cold 
70% ethanol and re-centrifuged at top speed (minimum 4000g). The pellet was air dried
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for 10 min. The DNA was dissolved in 100 jj.1 TE buffer (10 mM Tris HC1; 1 mM EDTA, 
pH 8.0). After treatment with 2 pg/ml RNase solution for 30 minutes at 37°C, the DNA 
sample was diluted, 2 pi into 1000 pi distilled water, and the DNA samples were placed 
in a quartz cuvette in order to read the optical density (OD). The concentration o f DNA 
was read by measuring the absorbance o f a sample at 260nm (A2 6 0 ) on a UV-visible 
recording spectrophotometer (Shimadaza, Kyoto, Japan). A 1.8% agarose gel was made 
with 0.6 g agarose containing ethidium bromide (0.5 pg m l'1) in 40 ml TBE buffer (89 
mM Tris base; 89 mM Boric acid; 2 mM EDTA, pH 8.2). 10 pg DNA samples in 1/5 
DNA volume of 6 x loading buffer (0.25% bromophenol blue; 0.25% xylene cyanol;
30% glycerol) were loaded on the agarose gel and electrophoresed at 100 volts until the 
dye marker had migrated almost to be bottom of the gel. 1 kb plus DNA ladder (Life 
Technologies, Rockville, MD, USA) was used as the molecular weight DNA marker. 
After electrophoresis, the gel was visualized under UV light, and photographed using a 
Kodak DC 120 zoom digital camera (Eastman Kodak Company, Rochester, NY. USA).
12. FLOW CYTOMETRY ANALYSIS OF CELL CYCLE
The method is based on elution o f low-molecular weight DNA from the ethanol- 
fixed cells, which is followed by cell staining with propidium iodide (PI; Sigma, St.
Louis, MO. USA) as the DNA fluorochrome. PI binds to the major groove o f double­
stranded DNA after permeabilization o f cells, which produces a highly fluorescent adduct 
that can be excited at 488 nm with a broad emission centered around 600 nm. Since PI 
can also bind to double-stranded RNA, it is necessary to treat the cells with RNase for
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optimal DNA resolution (Banerjee et al., 1997; Krishan, 1975). The relative content of 
DNA indicates the distribution o f a population of cells throughout the cell cycle. For 
cycling cells, cells in the Go/Gi phases of the cell cycle have a diploid DNA content (2n). 
Cells within the G2/M phases have a DNA content o f 4n, while S phase has a DNA 
content greater than 2n and less than 4n (DNA synthetic) during which the DNA content 
has doubled (Ormerod, 1999).
The experimental groups consisted of cells treated with three concentrations of 
Arglabin-DMA (15.25 and 30.50 pM). Also, 19.5 pM 5-Fluorouracil was used for a 
positive control to demonstrate correctly stained cells and cell cycle effects. 5- 
Fluorouracil is a potent antitumor agent that affects pyrimidine synthesis by inhibiting 
thymidylate synthetase. Treatment of cells with 5-FU leads to an accumulation of cells in 
S-phase (Takeda et al., 1999). Cells which were not subjected to any treatment with the 
drug were used as a negative control. HCT 116 and HT-29 cells were seeded at a density 
o f 2 x 104 cells/cm2. After 24 hours incubation in a CO2  incubator, the media in the flasks 
were replaced with fresh media or with media containing Arglabin-DMA (15.25 and
30.50 pM) or 5-Fluorouracil (19.5 pM). The cells were incubated for a further 24 hours.
For each time interval, a cell pellet was obtained by centrifugation of floating 
cells and attached cells. The pellet was then washed once with 1 x PBS (0.14 M NaCl; 3 
mM KC1; 10 mM Na2 HPO; 2 mM KH2 PO4 , pH 7.2). It was fixed in 70% ethanol and 
stored at 4 °C. At the time of processing, a pellet was obtained by centrifugation o f the
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samples at 2000 r.p.m. for 5 minutes. The resulting pellet was washed once with 1 x PBS 
and then resuspended in 3 ml of 1 x PBS.
100 pi o f 0.5 mg m l'1 RNase was added to each sample. The samples were 
incubated at 37 °C for 30 minutes. The samples were then stained with 40 pi o f 0.5 pg 
m l'1 propidium iodide. All samples were filtered through a 40 pM pore mesh to protect 
the nozzle of the flow chamber in cytometer. The samples were analyzed using two 
different flow cytometers: a FACSCalibur flow cytometer (Becton-Dickinson 
Biosciences: Immunocytometry Systems, San Jose, CA, USA) at Eastern Virginia 
Medical School or the Coulter EPCICS C clinical flow cytometer (Beckman Coulter, 
Miami. EL, USA) at Old Dominion University.
13. STATISTICAL ANALYSIS
We used three different final inoculation cell densities (4 x 103, 2 x 104, or 4 x 
104 cells/cm2). Cell growth in HCT 116 or HT-29 was tested with the addition o f three 
different concentrations (15.25, 30.50, or 45.75 pM) of Arglabin-DMA for three different 
durations (1, 2, or 3 days) o f incubation. Data under the same conditions were collected 
and analyzed. Samples chosen from data o f untreated HCT 116 or HT-29 cells were 
compared as control groups with data from cells treated with Arglabin-DMA in HCT 116 
or HT-29. The data files were analyzed using Adventures in Statistics 7.0 (SPSS, 
Syracuse, NY. USA). Statistical analysis shows that the critical t-value (teal) is greater 
than the observed t-values (t table), with the probability value (P-value).
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First, differences in all test results between decreased cell numbers in HCT 116 or 
HT-29 after treatment with Arglabin-DMA were analyzed by a 2-tailed Student's t test. 
We hypothesize that the decrease in total cell growth numbers after treatment with 
Arglabin-DMA in HCT 116 or HT-29 is not significantly different. The student t test was 
used to compare mean values, and statistical significance was achieved when P <0.05. 
Second, a Paired Student's t test was performed to compare both the percentage of 
decreased cell numbers between HCT 116 and HT-29. The null hypothesis is that there 
are no difference in growth inhibition between HCT 116 (ras-; K-ras mutant) and HT-29 
(ras +; wide type ras) after exposure of Arglabin-DMA. The cut-off level for statistical 
significance of differences was predetermined as P  <0.05 for all comparisons.
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RESULTS
1. REEXAMINATION OF THE ABILITY OF ARGLABIN-DMA TO INHIBIT 
FARNESYLATION OF RAS PROTEIN IN  VITRO. 
1.1. Cell Viability
In our studies, three concentrations (15.25, 30.50, and 45.75 pM) of Arglabin- 
DMA were used. Two cell lines of different ras status, HCT 116 and HT-29, underwent 
similar cell rounding and detachment after treatment with Arglabin-DMA (Figure 9 and 
10). Distribution of floating cells in HCT 116 and HT-29 was calculated from sixteen cell 
culture data sets. The range o f floating cells per ml for HCT 116 after exposure o f three 
different concentrations of Arglabin-DMA was 1.76 -  6.76 x 104 and for HT-29 it was
2.50 -  5.66 x 104 in a dose-dependent manner. The percentages o f floating cells to total 
cell number was 8-39%, and 9-32% , respectively (Table 3).
About 4 x 104 cells/cm2 were examined after 24hrs, because the population 
doubling times of both HCT 116 and HT-29 after exposure with Arlabin-DMA are about 
24 hours. Cells were cultured for three more days. After incubation with no drug (control) 
and three different concentrations of Arglabin-DMA, total cell numbers in HCT 116 or 
HT-29 decreased in direct relation to the concentration of Arglabin-DMA (Figure 11), 
and three different concentrations (15.25, 30.50 or 45.75 pM) of Arglabin-DMA led to a 
reduction in cell numbers o f 24.5%, 58.3%, and 66.2% in HCT 116, and by 11.8%,
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Figure 9 Morphology of floating cells and adherent cells in HCT 116. Adherent cells 
show anchorage-dependent growth, whereas floating cells show rounding and detachment 
after treatment with Arglabin-DMA (black arrow (->) indicates floating cell; gray arrow 
( ) indicates attached cells).
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Figure 10 Morphology of floating cells and adherent cells in HT-29. Adherent cells 
show anchorage-dependent growth, whereas floating cells show rounding and detachment 
after treatment with Arglabin-DMA (black arrow (-*) indicates floating cell; gray arrow 
( ) indicates attached cells).
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Table 3 Distribution of floating cells in HCT 116 and HT-29 after three different 
concentrations (15, 30 or 45 p.M) of Arglabin-DMA (Floating cells: rounding and 
detached cells)___________________________________________________________
Floating cells Mean (Cells/ml) Range (Cells/ml)
HCT 116 3.54 x 104 1.76 -  6.76 x 104(8-39% )
HT-29 3.74 x 104 2 .5 0 -5 .6 6  x 104 (9-32% )
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Figure 11 Inhibition of cell growth after exposure to Arglabin-DMA in HCT 116 or 
HT-29 cells. (C: untreated drug (Control), 15A: 15.25 pM Arglabin-DMA, 30A: 30.50 
pM Arglabin-DMA, 45A: 45.75 pM Arglabin-DMA).
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67.4%, and 69.1% in HT-29 relative to the control values (Figure 12). Arglabin-DMA 
thus inhibits the proliferation of both cultured human colon tumor cells (HCT 116 and 
HT-29), having different ras status in vitro. It is probable that reduction in cell number 
after treatment with Arglabin-DMA is not affected by ras status.
Changing the cell number in the inoculation produced a significantly different 
result in regards to cell growth. Three different inoculation cell sizes (4 x 103, 2 x 104, 
and 4 x 104 cells/cm2) were used. Cell growth in HCT 116 or HT-29 was tested with the 
addition of three different concentrations o f Arglabin-DMA (Figure 13 and Table 4). 
Also, the percentage o f inhibition o f cell growth in each group of the various 
concentrations of Arglabin-DMA was calculated by comparing the untreated group and 
the Arglabin-DMA treated group (Figure 14 and Table 5). It was determined that 
inhibition o f cell growth was directly related to the concentration of Arglabin-DMA, and 
inversely related to the total cell number o f inoculation in both HCT 116 and HT-29. 
Arglabin-DMA inhibits tumor cell growth in a dose-dependent manner. Also, no 
difference is seen between cell lines based on Ras status.
Although many anticancer drugs have been developed that have proven to inhibit 
the growth of cancer cells in vitro, many o f these treatments involve chemicals that may 
also injure normal cells in cancer patients, resulting in impaired cell functioning. Serious 
harm to normal cells by anticancer drugs is an important problem in the development of 
drugs. After 72 hours of incubation with several positive controls (30.50 pM Arglabin-
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C e l l  l i n e s
Figure 12 Percentage of cell growth inhibition after exposure of Arglabin-DMA in 
HCT 116 and HT-29 cells. (15A: 15.25 pM Arglabin-DMA, 30A: 30.50 pM Arglabin- 
DMA, 45A: 45.75 pM Arglabin-DMA).
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Figure 13 Percent inhibition of cell growth between inoculation numbers and 
concentrations of Arglabin-DMA in the HCT 116 cell line. (15A: 15.25 jaM Arglabin- 
DMA, 30A: 30.50 (aM Arglabin-DMA, 45A: 45.75 |aM Arglabin-DMA).
Table 4 Percent inhibition of cell growth between inoculation numbers and
concentrations of Arglabin-DMA in the HCT 116 cell line
HCT 116 (cells/cm2) 15A 30A 45A
4 x 10J 88.58% 97.40% 100%
2 x 104 35.02% 74.31% 84.39%
4 x 104 12.15% 62.13% 69.10%
(15A: 15.25 jaM Arglabin-DMA, 30A: 30.50 ^iM Arglabin-DMA, 45A: 45.75 |aM 
Arglabin-DMA).
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Figure 14 Percent inhibition of cell growth between inoculation numbers and the 
concentrations o f Arglabin-DMA in the HT-29 cell line. (15A: 15.25 pM Arglabin-DMA, 
30A: 30.50 pM Arglabin-DMA, 45A: 45.75 pM Arglabin-DMA).
Table 5 Percent inhibition of cell growth between inoculation numbers and the
concentrations o f Arglabin-DMA in the HT-29 cell line
HT-29 (cells/cm2) 15A 30A 4SA
4 x 10J 97.09% 95.81% 99.53%
2 x 104 41.60% 70.94% 91.74%
4 x l®4 16.04% 29.18% 69.10%
(15A: 15.25 pM Arglabin-DMA, 30A: 30.50 pM Arglabin-DMA, 45A: 45.75 pM 
Arglabin-DMA).
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DMA, 19.5 pM 5-Fluorouracil, 10 pM Lovastatin, or 58 nM Taxol), Arglabin-DMA was 
examined to investigate relative toxic effects in normal cells (Hs27, fibroblast) in 
comparison with these other drugs.
Cell growth after exposure to Arglabin-DMA in HCT 116 or HT-29 cell lines was 
significantly inhibited: 79.13% or 77.06% decrease in total cell numbers, respectively 
(Figure 15, 16). Taxol in HCT 116 and HT-29 inhibits 84.20% and 78.40% o f cell growth. 
5-Fluorouracil in HCT 116 and HT-29 inhibited 64.57% and 69.31% cell growth. 
Arglabin-DMA, 5-FU, and Taxol thus significantly inhibit cell growth in both human 
tumor cell lines. In contrast, HCT 116 cells treated with Lovastatin decresase 52.39%, 
while HT-29 had only a slight decrease (19.01%) in cell growth. Our study showed that 
Lovastatin is thus highly effective in mutant K-ras HCT 116 cells, but not in normal ras 
HT-29 cells. The inhibition of cell growth due to treatment with Arglabin-DMA is similar 
to that o f Taxol, and slightly greater than 5-FU and Lovastatin. Statistical analysis o f cell 
growth inhibition between each drugs compared with Arglabin-DMA in HCT 116 or HT- 
29 cell lines showed that Arglabin-DMA affects cell growth inhibition as that of Taxol or 
5-FU and is more effect than Lovasatin (Figure 15, 16).
In a normal cell line (Hs27), cells treated with Lovastatin or Taxol decreased cell 
survival by 68.71% and 57.82% after three days o f incubation. The 5-FU treated group 
was reduced 43.30%. Arglabin-DMA inhibited 41.58% cell growth in Hs27. Statistical 
analysis showed that the probability value o f both Taxol and Lovastatin compared with
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F ig u re  15 Arglabin-DMA cytotoxicity in HCT 116 after three days incubation. (30.50 
|iM Arglabin-DMA, 19.5 jaM 5-Fluorouracil, 10 |iM Lovastatin, 58 nM Taxol).
4- : P= 0.202, Taxol vs. Argalbin-DMA.
4  4- : P= 0.120, 5-Fluorouracil vs. Argalbin-DMA.
4-4-4- : P= 0.001, Lovastatin vs. Argalbin-DMA.
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Figure 16 Arglabin-DMA cytotoxicity in HT-29 cell line after three days incubation. 
(30.50 |oM Arglabin-DMA, 19.5 p.M 5-Fluorouracil, 10 p.M Lovastatin, 58 nM Taxol).
♦  : P= 0.833, Taxol vs. Arglabin-DMA.
♦  4  : P= 0.268, 5-Fluorouracil vs. Arglabin-DMA.
♦  +  +  : P= 0.010, Lovastatin vs. Arglabin-DMA.
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Arglabin-DMA in HCT 116 or HT-29 cell lines are smaller than 0.05; in contrast, the 
probability value, compared with 5-Fluorouracil, showed greater than 0.05 (Figure 17). 
Therefore cell growth inhibition of Arglabin-DMA in normal Hs27 is less than that of 
Lovastatin or Taxol, and is similar to that o f 5-FU. After three or eight days incubation 
with Arglabin-DMA or Taxol, it was found that the viability of Hs27 cells treated with 
Arglabin-DMA had increased from 41.38% to 53.01%. The groups treated with Taxol 
had a more dramatic decrease in total cell growth (68.97% to 85.79%) (Figure 18 and 
Table 6). This signifies that normal cells (Hs27) are less susceptible to Arglabin-DMA- 
induced toxicity, and the drug has less potential for inhibiting normal cell growth, 
particularly after longer exposures.
1.2. Statistical analysis
Changing the cell number o f the inoculation, the concentration o f drug, or the 
incubation time in both human colon tumor cell lines (HCT 116 or HT-29) produced 
significantly different results in regards to cell growth and viability.
To examine whether Arglabin-DMA inhibits specifically mutant K-ras tumor 
colon cells or not, statistical analysis was executed to analyze cell culture data obtained 
from each experiment. The results o f the t test for both HCT 116 and HT-29 were 
significant when cell lines treated with Arglabin-DMA were compared to the untreated 
control (Table 7). Therefore, cell growth inhibition by Arglabin-DMA in HCT 116 or 
HT-29 has a significant effect. Also, we compared toxicity in HCT 116 and HT-29 after
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Figure 17 Cytotoxicity in Hs27 after three days incubation with four anticancer drugs. 
(30.50 |jM Arglabin-DMA, 19.5 |iM 5-Fluorouracil, 10 (j,M Lovastatin, 58 nM Taxol). 
+  : P= 0.028, Taxol vs. Arglabin-DMA.
♦  ♦  : P= 0.073, 5-Fluorouracil vs. Arglabin-DMA.
♦  ♦  ♦  : P= 0.007, Lovastatin vs. Arglabin-DMA.
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Taxol (Day 3 incubation) Taxol (Day 8 incubation)
Figure 18 The morphological cell changes in Hs27 after two different incubation 
periods (three or eight days) after treatment with Arglabin-DMA or Taxol. (A and B: 
Untreated-control group, C and D: 30 pM Arglabin-DMA, E and F: 58 nM Taxol).
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Table 6 Percentage o f cell growth inhibition in Hs27 after two different incubation 
periods (three or eight days) after treatment with Arglabin-DMA or Taxol ______
Hs27 Day 3 (cells/cm2) Day 8 (cells/cm2)
Control 5.24 x 104 1.10 x lO5
30 pM Arglabin-DMA 3.06 x 104 (41.38%) 5.16 x 104 (53.01%)
58 nM Taxol 1.62 x 104 (68.97%) 1.56 x 104 (85.79%)
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Table 7 Statistical analysis of decline of the total cell number between control group 
and Arglabin-DMA group 
A
HCT 116 t-test for Equality of Means
Two sample test t cai. t table P-value Ho: Uj = Uj
Control - Drug 3.488 2.0322 0.001 Reject Ho
B
HT 29 t-test for Equality of Means
Two sample test t  cai. t table P-value Ho: Uj = Uj
Control - Drug 2.105 2.0322 0.043 Reject Ho
A: HCT 116 cell line, B: HT-29 cell line.
Ho: Uj = Uj, (Uj = Hypothetical value) 
t  table = A),05(2). df, (df = n-1, n=sample number) 
11 cai | < t  table (P>0.05) then do not reject Ho 
I t  cai. | ^ t  table (P<0.05) then reject Ho
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exposure to Arglabin-DMA (Table 8) and found that there was no significant difference 
in toxicity between the two cell lines (HCT 116 or HT-29). Therefore, statistical analysis 
indicated that Arglabin-DMA equally affects cell growth inhibition in both wild-type ras 
and mutant K-ras tumor cells.
1.3. Add-Back experiments
Higher doses of Lovastatin, Manumycin A, and Arglabin-DMA at 90% inhibitory 
concentrations for HCT 116 were used in these experiments to clarify the inhibiting 
potential o f these drugs. Total cell numbers o f HCT 116 (ras-) after Lovastatin treatment 
were decreased by 79.89%, but only 32.92% in HT-29 (ras+). In the group treated by 
both famesyl pyrophosphate and Lovastatin in HCT 116 and HT-29, the number o f viable 
cells decreased in comparison to the only Lovastatin treated group. In contrast, the group 
treated by both geranylgeranyl pyrophosphate and Lovastatin in HCT 116 significantly 
increased cell growth (85.99%) compared to the data of Lovastatin treated group (20.11%) 
(Figure 19). Also, detached HCT cells induced by Lovastatin were reattached in the 
group treated by both geranylgeranyl pyrophosphate and Lovastatin in HCT 116 cell 
(data not shown). In HT-29, cell growth rate in between the group treated by Lovastain 
and the group treated by geranylgeranyl pyrophosphate and Lovastatin changed 65% to 
82% (Figure 19). T h e  geranylgeranyl pyrophosphate slightly prevented the cell growth 
inhibition by Lovastatin. These data imply that geranylgeranyl pyrophosphate prevented 
Lovastatin-induced cell rounding and detachment, suggesting that Lovastatin may act by 
inhibiting geranylgeranylation and not famesylation o f target proteins. Manumycin A
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Table 8 Statistical analysis o f the percent o f decrease in cell number between HCT 116 
and HT-29 cell lines after treatment with Arglabin-DMA____________________________
Cell line t-test for Equality of Means
Paired test t  cai. t  table Sig.(2-tail) Ho: tfs = 0
HCT 116-H T -29 1.562 2.1098 0.137 Accept Ho
Ho: Uj = 0
t  table = *0 .0 5 (2 ), df, (df = n-1, n=sample number) 
11 cai I < t  table (P>0.05) then do not reject Ho 
I t  cai. | > t  table (P<0.05) then reject Ho
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Figure 19 Add-back experiment after treatment with Lovastatin. Lovastatin in both 
HCT 116 and HT-29 after three days incubation inhibits polyprenylation and the 
formation of isoprenoids. (famesyl pyrophosphate and geranylgeranyl pyrophosphate). 
(L: 30 pM Lovastatin, M: FPP: 100 pM Famesyl pyrophosphate, GGPP: 10 pM 
geranylgeranyl pyrophosphate).
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was chosen because FPP is a substrate not only for FTase but also for other enzymes 
catalyzing the synthesis of squalene and other prenylation reactions and is expected to 
affect the isoprenoid biosynthetic pathway. The result is that Manumycin A did not affect 
the groups with added isoprenoid (Figure 20). Significantly, in spite of higher 
concentration o f Manumycin A, it slightly affected FIT-29 cells (ras-) (24.25%) 
compared to cell growth inhibition (5.34%) o f HCT 116 cells (ras+). Arglabin-DMA, in 
contrast significantly inhibited cell growth in both colon tumor cell lines. Addition of 
isoprenoid (famesyl pyrophosphate or geranylgeranyl pyrophosphate) did not relieve 
inhibition in either cell line (Figure 21). Therefore, Arglabin-DMA had no effect on the 
isoprenylated proteins, and the data with Arglabin-DMA is similar to that of Manumycin 
A. In contrast, inhibition o f geranylgeranylation is the probable mechanism of action of 
Lovastatin. These results cast doubt on the suggested FTI-based mechanism of inhibition 
for Arglabin-DMA.
2. TEST OF WHETHER ARGLABIN-DMA INHIBITS CANCER CELL 
GROWTH IN AN APOPTOSIS-DEPENDENT MANNER.
2.1. Annexin V assay
We have observed that colon tumor cells lose their ability to maintain an 
asymmetric lipid bilayer after exposure to Arglabin-DMA. The most pronounced feature 
of this normal asymmetry is the significant absence of phosphatidylserine (PS) in the
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
A d d -B a c k  e x p e r im e n t  
(M an u m ycin  A)
HCT 1 16  (R a s -)  H T-29 (R a s+ )  
C ell lin e s
■  M
□  M +FPP
□  M +G G PP
Figure 20 Add-back experiment after treatment with Manumycin A. Manumycin A in 
both HCT 116 and HT-29 after three days incubation inhibits polyprenylation and the 
formation o f isoprenoids. (famesyl pyrophosphate and geranylgeranyl pyrophosphate). 
(M: 20 pM Manumycin A, FPP: 100 pM Famesyl pyrophosphate, G: 10 pM 
geranylgeranyl pyrophosphate).
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Figure 21 Add-back experiment after treatment with Arglabin-DMA. Arglabin-DMA 
in both HCT 116 and HT-29 after three days incubation inhibits polyprenylation and the 
formation o f isoprenoids. (famesyl pyrophosphate and geranylgeranyl pyrophosphate). 
(A: 61 pM Arglabin-DMA, FPP: 100 pM Famesyl pyrophosphate, GGPP: 10 pM 
geranylgeranyl pyrophosphate).
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outer leaflet o f the plasma membrane. During the initial phase o f apoptosis, phospholipid 
redistribution caused by membrane alterations is detected. When PS is exposed, Annexin 
V binds specifically to the phospholipid membrane in the presence of Ca2+ ions (Vermes 
and Haanen, 1994). Apoptotic cells are distinguished by using Annexin V as an EGFP 
(enhanced green fluorescent protein) conjugate in combination with propidium iodide 
(PI). Annexin V-EGFP is the brightest green fluorescent reagent available for Annexin 
V-based detection o f apoptosis (Koopman et al., 1994).
After being treated with 30 pM Arglabin-DMA in HCT 116 and HT-29, early 
apoptotic cells with intact cell membranes stained green (Annexin V positive/PI negative) 
were detected through photography at three days in floating cells (Figures 22 and 23). 
Also, dimly stained green cells that did not have enough intensity to be detected by 
photography were present in both attached and floating groups. Arglabin-DMA thus 
induces apoptosis in floating cells that form phospholipid redistribution based on 
membrane alterations. It is possible that apoptosis induced by Arglabin-DMA occurs in 
attached cells, perhaps representing an early stages of apoptosis that will be followed 
later by detachment.
2.2. Apoptosis dye-uptake assay
Cell uptake o f a purple-red dye happens only in the apoptotic process (Figure 24). 
Colon tumor cells (HCT 116 and HT-29) not treated with Arglabin-DMA did not exhibit 
dye uptake. Small numbers of cells in the attached HCT 116 and HT-29 cells undergo
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Figure 22 Annexin V assay in HCT 116. Early apoptotic cells in floating cells, after 
treatment with 30.5 pM Arglabin-DMA for three days incubation.
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Fignnre 23 Annexin V assay in HT-29. Early apoptosis in floating cells treated with 30.5 
pM Arglabin-DMA for three days incubation.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Figure 24 Image of apoptotic cells in Apopercentage assay. HCT 116 and HT-29 cells 
undergoing apoptosis have become visible by purple-pink dye. Black arrow (->) 
indicates apoptotic cell.
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apoptosis after exposure to Arglabin-DMA. After one day incubation with Arglabin- 
DMA, 13.39% of floating HCT 116 cells were apoptotic. Under the same conditions, 
29.43% of floating group in HT-29 were apoptotic. At three days, over 26% of floating 
HCT 116 and HT-29 cells were apoptotic (Figures 25 and 26; Tables 9 and 10). Thus, 
early phase apoptotic cells, stained by Apopercentage dye, were increased in Arglabin- 
DMA induced floating cells on HCT 116 and HT-29.
2.3. Identification of dying cells by apoptotic nuclear morphology
Cells dying by apoptosis usually undergo characteristic morphological and 
biochemical changes. The types o f morphological change consist o f membrane blebbing, 
chromatin condensation, nuclear breakdown, and cytolysis into condensed apoptotic 
bodies. Dramatic changes occur within the nucleus during apoptotic death (Vermes and 
haanen, 1994). Cells undergoing apoptosis display increased chromatin condensation and 
nuclear fragmentation. These morphological changes are triggered by the activation of 
members o f the caspase family including caspase activated DNase, and several novel 
proteins including AIF (apoptosis-inducing factor) and CIDE (Cell death-inducing DFF- 
like Effector) (Kroemer and Zamzami, 1999). An apoptotic chromatin condensation 
inducer in the nucleus, Acinus, induces apoptotic chromatin condensation. Acinus is 
cleaved by caspase-3 and an additional unknown protease, generating a small active 
peptide p i 7, which causes chromatin condensation in vitro (Sahara et al, 1999).
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Figure 25 Apoptosis dye-uptake assay in HCT 116. Percentage apoptotic cells after one 
and three days incubation following treatment with 30.5 pM Arglabin-DMA.
Table 9 Apoptosis dye-uptake assay in HCT 116
Incubation Cell type Untreated 30A Attached 30A Floating
day Group Group Group
Normal cells 1.23 x 10b 5.33 x 10b 1.27 x lO3




4.24 x 103 
(0.80%) 
1.06 x 106
1.70 x 104 
(13.39%) 
1.98 x 105
3 days Apoptotic cells 0 (0%) 4.35 x 104 (4.10%)
5.16 x 104 
(26.06%)
The number o f apoptotic HCT 116 cells.
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Figure 26 Apoptosis dye-uptake assay in HT-29. Percentage apoptotic cells after one and 
three days incubation following treatment with 30 pM Arglabin-DMA.
Table 10 Apoptosis dye-uptake assay in HT-29
Incubation Cell type Untreated 30A Attaching 30A Floating 
day_________________________ Group ________ Group _________ Group








6.68 x 104 
(29.43%) 
2.83 x 105
3 days Apoptotic cells 0 (0%)
4.69 x 103 
(0.34%)
7.53 x 104 
(26.61%)
The number o f apoptotic HT-29 cells.
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Fluorescent DNA-binding dyes, such as ethidium bromide (EB), are taken up only 
by dying cells. EB fluoresces a red-orange color under ultraviolet light and with increased 
fluorescence when bound to double-stranded DNA. Metachromatic dye acridine orange 
(AO) can be taken up by both live and dead cells, which can be distinguished by their 
different morphologies. AO intercalates into DNA (green) and also binds to RNA (red- 
orange). The difference in the uptake of these two dyes (AO/EB) allows the identification 
o f viable versus non-viable cells by fluorescence microscopy. An assay o f cell viability 
based on simultaneous cell staining with AO and EB allows one to discriminate between 
live vs. apoptotic vs. necrotic cells (Reed, 2000).
In Tables 11 and 12, over 95% HCT 116 or HT-29 cells not exposed to Arglabin- 
DMA are live cells (Stage 1; Figure 27; A). After exposure to Arglabin-DMA, many 
attached cells in HCT 116 or HT-29 cell line were live in Stage 1, while over 80% 
floating cells in HCT 116 or HT-29 were in Stages 2 and 3 (Figures 27; B and C). 
However, fewer than 8% of attached cells in HCT 116 and HT-29 showed morphologies 
classified as Stage 2 (Figure 27; B). Floating cells in HCT 116 and HT-29 after treatment 
with Arglabin-DMA were identified as apoptotic cells in Stage 4, which includes bright 
orange chromatin that is fragmented, or apoptotic bodies in the late phase o f apoptosis 
(Figure 27; D). Red color cells, Stage 5, are dead cells, (Figure 27, C and E). The 
increase o f dead cells in the untreated group is attributed to nutritional deficiencies in the 
medium due to the increased growth o f colon tumor cells.
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Figure 27 Identification o f dying cells by apoptotic nuclear morphology. A: Stage one 
- bright green chromatin with organized cell structure: viable cells with normal nuclei 
(uniform distribution). B: Stage two - bright green chromatin that is highly condensed or 
fragmented: viable cells with apoptotic nuclei, early phase of apoptosis. C: Stage three or 
four - bright orange chromatin (uniform staining) that is highly condensed or fragmented: 
nonviable cells with apoptotic nuclei, late phase of apoptosis. D: Stage four - bright 
orange chromatin that is highly fragmented: nonviable cells with apoptotic nuclei, late 
phase o f apoptosis. E: Stage five - red cell (lower left) that is a dead cell.
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Table 11 Identification o f dying cells by apoptotic nuclear morphology
HCT 116 TCN Stage
1 2-3 4 5
Control Group 8.87 x 106 96.08% negligible none 3.92%
Attached Group 1.06 x 106 91.36% 7.41% (Stage 2) none 1.24%
Floating group 1.98 x 105 2.59% 86.2% 4.31% 6.90%
Morphological changes after treatment with 30.5 pM Arglabin-DMA for three days 
incubation in HCT 116. (TCN: Total cell number).
Stage 1 = Bright green chromatin with organized cell structure -  Normal cells.
Stage 2 = Bright green chromatin that is highly condensed -  Early phase o f apoptosis. 
Stage 3 = Bright orange chromatin that is highly condensed - Late phase o f apoptosis. 
Stage 4 = Bright orange chromatin that is fragmented - Late phase o f apoptosis.
Stage 5 = Red cells -  Dead cells.
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Table 12 Identification o f dying cells by apoptotic nuclear morphology
HT-29 TCN Stage
1 2-3 4 5
Control Group 7.47 x 106 95.74% negligible none 4.26%
Attached Group 1.40 x 106 56.60% 32.08% (Stage 2) none 8.93%
Floating Group 2.83 x 105 4.35% 81.16% 11.59% 2.90%
Morphological changes after treatment with 30.5 pM Arglabin-DMA for three days 
incubation in HT-29. (TCN: Total cell number).
Stage 1 = Bright green chromatin with organized cell structure -  Normal cells.
Stage 2 = Bright green chromatin that is highly condensed -  Early phase o f apoptosis. 
Stage 3 = Bright orange chromatin that is highly condensed - Late phase o f apoptosis. 
Stage 4 = Bright orange chromatin that is fragmented - Late phase o f apoptosis.
Stage 5 = Red cells -  Dead cells.
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Typical early or late apoptotic morphological changes induced by Arglabin- 
DMA were observed in the floating cells of HCT 116 and HT-29 cell lines, including 
evident cytoplasmic and nuclear shrinkage, chromatin condensation, and membrane 
blebbing, which are all characteristic morphological alterations o f apoptosis (Figure 27; B, 
C, and D). Also, early phase apoptotic cells, with bright green chromatin that is highly 
condensed, were observed in the attached cells treated with Arglabin-DMA. Therefore, 
Arglabin-DMA induced apoptosis in floating cells and to a lesser degree in attached cells.
2.4. TUNEL assay
The DNA strand-breaks o f the untreated group generated by TACS-Nuclease in 
the positive control have uniform brown staining in HCT 116 or HT-29 (Figures 28). A 
negative control sample omitted terminal deoxynucleotidyl transferase (TdT) in the 
enzymatic reaction (not shown but very similar to Figure 29).
The attached group treated with Arglabin-DMA, in both colon tumor cell lines, 
was no different than the negative control sample (Figure 29). This indicates that the 
anchorage-dependent cells did not have the free 3-hydroxyl residues o f DNA fragments, 
and apoptotic cells were not found in the attaching group after the exposure to Arglabin- 
DMA. No apoptotic cells were detected in the untreated sample or the attached cells of 
HCT 116 and HT-29 exposed to 30 pM Arglabin-DMA. The 10-30% floating cells could 
not be monitored because anchorage-dependent cells were the only types examined.
These floaters are likely the apoptotic population.














Figure 28 Positive control of TUNEL assay. DNA strand breaks generated by nuclease 
in essentially every untreated cell were stained as brown color (A: HCT 116 B: HT-29).
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Figure 29 TUNEL assay in attached cells after treatment with 30.5 pM Arglabin-DMA 
for three days (A: HCT 116 B: HT-29).
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2.5. Analysis of DNA fragmentation
As a positive control, we used Taxol since this drug induces morphological 
changes like Arglabin-DMA and has the ability to induce apoptosis. As seen in DNA 
fragmentation assays, in the floating cells in HCT 116 or HT-29, exposure to 58 nM 
Taxol results in DNA ladder formation within one day, whereas fragmentation was 
absent in the untreated sample or the attached sample exposed to 30 pM Arglabin-DMA 
(Figure 30 and 32). However, after Arglabin-DMA or Taxol treatment, DNA 
fragmentation increased in the floating HCT 116 cells after three days o f incubation 
(Figure 31). Similarly in the floating HT-29 cells, DNA ladder bands were detected 
similar to HCT 116 (Figure 33). Lovastatin induced morphological changes like 
Arglabin-DMA in HCT 116. The floating HCT 116 cells showed ladder bands after three 
days o f incubation (Figure 34). DNA fragmentation was still not detectable in the 
untreated sample, or drug treatment (Arglabin-DMA or Taxol) in the attached cells of 
ether cell line. Cell death induced by Taxol was more rapid than by Arglabin-DMA.
Data from the DNA fragmentation assay showed that floating cells had undergone 
apoptosis. In an additional experiment, we examined the relationship between p53 and 
apoptosis. Taxol and Lovastatin were used as positive controls for this experiment. In 
previous studies, Taxol was shown to display p53-independent apoptosis. (Lanni et al., 
1997; O'Connor et al., 1997). Lovastatin has been shown to induce p53-dependent 
apoptosis in human colon tumor cells (Agarwal et al., 1999). After exposure to Arglabin- 
DMA, Lovastatin, or Taxol in each of the cell lines, HCT 116, HT-29 and Hs27, we
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Fngunir© 3® Analysis o f DNA fragmentation in HCT 116 after 24 hours incubation with 
30.5 |jlM Arglabin-DMA or 58 nM Taxol. (M: Molecular Marker; 1 kb plus DNA ladder, 
1: Control-untreated cells, 2: Attached cells treated with Arglabin-DMA, 3: Floating cells 
treated with Arglabin-DMA, 4: Attached cells treated with Taxol, 5: Floating cells treated 
with Taxol).
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Figure 31 Analysis o f DNA fragmentation in HCT 116 after three days incubation with 
30.5 (iM Arglabin-DMA or 58 nM Taxol. (M: Molecular Marker; 1 kb plus DNA ladder,
1: Control-untreated cells, 2: Attached cells treated with Arglabin-DMA, 3: Floating cells 
treated with Arglabin-DMA, 4: Attached cells treated with Taxol, 5: Floating cells treated 
with Taxol).
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Fngunir® 32 Analysis o f DNA fragmentation in HT-29 after one day incubation with 30.5 
|j,M Arglabin-DMA or 58 nM Taxol. (M: Molecular Marker; 1 kb plus DNA ladder, 1: 
Control-untreated cells, 2: Attached cells treated with Arglabin-DMA, 3: Floating cells 
treated with Arglabin-DMA, 4: Attached cells treated with Taxol, 5: Floating cells treated 
with Taxol).
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Figure 33 Analysis of DNA fragmentation in HT-29 after three days incubation with 
30.5 (iM Arglabin-DMA or 58 nM Taxol. (M: Molecular Marker; 1 kb plus DNA ladder, 
1: Control-untreated cells, 2: Attached cells treated with Arglabin-DMA, 3: Floating cells 
treated with Arglabin-DMA, 4: Attached cells treated with Taxol, 5: Floating cells treated 
with Taxol).
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Figure 34 Analysis of DNA fragmentation in two human colon tumor cell lines after 
three days incubation with 10 pM Lovastatin. (M: Molecular Marker; 1 kb plus DNA 
ladder, 1: Control-untreated cell o f HCT 116, 2: Attached cell treated with Lovastatin in 
HCT 116, 3: Floating cell treated with Lovastatin in HCT 116, 4: Control-untreated cells 
o f HT-29 5: Attached cells treated with Lovastatin in HT-29, 6. Floating cells treated 
with Lovastatin in HT-29).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
counted the number o f floating cells in each drug group. Both HCT 116 and Hs27 cells, 
having wild-type p53, showed increased numbers o f floating cells after exposure to 
Lovastatin. The number o f floating cells decreased significantly within the HT-29 cell 
line (p53 mutant) after treatment with Lovastatin in comparison with HCT 116 or Hs27 
cell lines. Taxol, however, proved to increase the number o f floating cells in all three cell 
lines. After exposure to Arglabin-DMA, the number of floating cells that resulted was 
shown to be similar to the number o f floating cells after treatment with Taxol in all three 
cell lines (Table 13). The number of floating cells with Lovastatin in HT-29, having 
mutant p53, decreased abruptly. This indicates that Lovastatin may induce p53-dependent 
apoptosis. The numbers o f floating cells o f the three cell lines treated with Arglabin- 
DMA were similar to that o f floating cells exposed to Taxol, which induces p53- 
independent apoptosis. This implies that Arglabin-DMA may induce p53-independent 
apoptosis.
3. TESTING WHETHER ARGLABIN-DMA INDUCES CELL CYCLE ARREST 
IN HUMAN COLON TUMOR CELL LINES.
3.1. Flow cytometry analysis of the cell cycle
In analysis o f the cell-cycle profile, each phase of the cell cycle was displayed 
with respect to DNA content. Thus, flow cytometry analysis o f DNA content revealed 
whether Arglabin-DMA treated cells arrest in G2/M.
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Table 13 The relation between p53 and floating cells undergoing apoptosis






5 x 104 (6.53%)
1.98 x 105 (27.12%) 
6.7 x 104 (13.99%)
2.08 x 10s (11.35%) 
7.63 x 105 (18.26%) 
3.07 x 105 (22.13%)
2.51 x 105 (9.46%) 
1.19 x 104 (1.27%) 
4.07 x 105 (16.23%)
Three cell lines (HCT 116, HT-29 and Hs27), either wild-type or mutated p53, were 
grown to subconfluence, exposed to the respective drugs (30.5 jjM  Arglabin-DMA, 10 
pM Lovastatin or 58 nM Taxol) for 3 days and the number of floating cells was counted.
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As shown in Figure 35 and Table 14 using a FACSCalibur (Becton-Dickinson 
flow cytometer) at Eastern Virginia Medical School, untreated HCT 116 cells exhibited a 
typical cell cycle distribution (72.31% in Gi, 20.26% in S phase, and 7.43% in G2 /M 
phase). When those were exposed to 19.5 pM 5-FU as a positive control, we observed 
48.58% in Gi, 48.70% in S phase, and 2.72% in G2 /M phase. Therefore, 5-FU reduces the 
number o f cells entering the G2 /M phase of the cell cycle as compared to the untreated 
sample. 15. 25 pM or 30.5 pM Arglabin-DMA treatment altered the cell cycle o f the 
HCT 116 cells, arresting them in G2 /M phase. In data from the Becton-Dickinson flow 
cytometer, the Arglabin-DMA treated group again showed an increased yellow peak 
(tetraploid: 4n) in the G2 /M phase (Figure 35).
After exposure 15.25 pM Arglabin-DMA in the HCT 116 cell line, using the 
Coulter flow cytometer, the data showed that the result is an increase in cells blocked at 
G2 /M phase (Figure 36 and Table 15). The results that HCT 116 cells treated with 
Arglabin-DMA showed the arrest o f G2 /M phase at 24 hours is similar to the results of 
Becton-Dickinson flow cytometer. In Coulter flow cytometric analysis in HT-29 cells, 
cells with two different concentrations o f Arglabin-DMA accumulated in G2/M by 24 
hours and decreased Gi and S phase population (Figure 37 and Table 16).
In summry, analysis with two different instruments showed flow cytometry 
profiles o f nuclear DNA content that revealed that Arglabin-DMA altered the DNA 
content and induced a G2/M phase arrest of cell cycle in HCT 116 and HT-29 cells.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
104
B
2 4 h  U
24h 15A
■ i i  i  r
C hannels




i m  p r t h - p > r i  H





Figure 35 DNA content frequency histograms of HCT 116 from a FACSCalibur 
(Becton-Dickinson flow cytometer). A: Untreated group, B: 15.25 pM  Arglabin-DMA, 
24 hrs, C: 30.5 pM  Arglabin-DMA, 24 hrs, D: 19.5 pM  5-FU. The red peak on the Gi or 
the G2 /M phase represents diploid cells. The yellow peak (tetraploid: 4n) is showed on 
the G2 /M phase of B and C graphes in Arglabin-DMA treatment group.
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Table 14 Flow cytometry analysis o f cell cycle in HCT 116 from a FACSCalibur 
(Becton-Dickinson flow cytom eter)_______________ ________________________
HCT 116 G, S g 2/m
A. Untreated (Control) 72.31 % 20.26 % 7.43 %
B. 15.25 p,M Arglabin-DMA 42.38 % 32.72 % 24.90 %
C. 30.5 pM Arglabin-DMA 28.57 % 37.78 % 33.65 %
D. 19.5 pM 5-Fluorouracil 48.58 % 48.70 % 2.72%




Figure 36 DNA content frequency histograms o f HCT 116 from the Coulter EPCICS C 
clinical flow cytometer. A: Untreated group, B: 15.25 pM Arglabin-DMA, 24 hrs.
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Table 15 Flow cytometry analysis of cell cycle in HCT 116 from the Coulter EPCICS C 
clinical flow cytometer _____________________________________________________
HCT 116 G, S g 2/m
A. Untreated (Control) 46.70 % 25.85 % 27.45 %
B. 15.25 piM Arglabin-DMA 26.54 % 15.54% 57.92 %







Figure 37 DNA content frequency histograms of HT-29 from the Coulter EPCICS C 
clinical flow cytometer. A: Untreated group, B: 15.25 pM Arglabin-DMA, 24 hrs, C: 
30.5 pM Arglabin-DMA, 24 hrs.
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Table 16 Flow cytometry analysis of cell cycle in HT-29 from the Coulter EPCICS C 
clinical flow cytometer_______________________________________________________
HT 29 G, S g 2/m
A. Untreated (Control) 45.58 % 27.79 % 26.63 %
B. 15 (J.M Arglabin-DMA 15.45% 15.28% 69.27 %
C. 30 \iM  Arglabin-DMA 21.85% 23.61 % 54.54 %
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DISCUSSION
A previous study suggested that Arglabin-DMA, modified to render it water- 
soluble, is a FTI that inhibits the binding of famesyl diphosphate (FDP) to FTase, thus 
inhibiting famesylation of Ras protein, and that Arglabin-DMA inhibits anchorage- 
independent growth of mouse neuroblastoma cells as well as KNRK cells (a normal rat 
kidney [NRK] cell line transformed by Kirsten murine sarcoma virus) (Shaikenov et al., 
2001). Our results showed that Arglabin-DMA has a marked effect on the morphology 
and the growth o f both mutant K-ras and wild-type ras human colon tumor cell lines 
(HCT 116 and HT-29), and these effects occur in a concentration-dependent manner. 
Cytotoxicity results, compared between the two colon tumor cell lines, suggested that 
those tumors that were sensitive to Arglabin-DMA were not dependent on Ras function 
activated by mutated K-ras. This means that Arglabin-DMA as an FTI does not 
specifically affect the activated Ras.
Preclinical studies on the response of cultured human tumor cells to FTI treatment 
showed that several cell types with wild-type ras are sensitive to FTIs, both in vivo and in 
vitro (Cox, 2001). In other studies, about 50% of K-ras transformed cell lines were 
observed to be as resistant as nontransformed cell lines, although it was very easy and 
straightforward to inhibit both processing and transformation as a result o f oncogenic H- 
Ras (Rowell et al., 1997). Proteins ending with a serine, such as H-Ras, bind more 
weakly to FPTase than proteins having a methionine, such as Ki4B-Ras and lamin B
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(Reiss el al., 1991). The differences in affinity imply that proteins in cells have different 
sensitivities to an FTI (Gibbs and Oliff, 1997). The basis for the resistance o f K-Ras to 
FTIs is that its affinity for the FTase enzyme is high (Rowell et al., 1997). It has been 
reported that K-Ras processing could escape FTI inhibition; nevertheless, tumors 
containing mutated K-ras could be inhibited by FTIs (Sepp-Lorenzino et al., 1995).
Another possible mechanism based on the cytotoxic data that Arglabin-DMA 
affects the growth of HCT 116 and HT-29 cell lines is that it affects the famesylation of 
one or more non-Ras proteins. It means that Arglabin-DMA may affect inhibition o f the 
processing o f other famesylated proteins. Famesylated proteins clearly have important 
roles to play in normal cells. Among the known famesylated CAAX proteins other than 
Ras, the G-proteins (for example, rap-1, rab, and rho), lamin A and B, and inositol 
triphosphate 5-phosphatase type I may have relevance to intracellular signaling and 
apoptosis (Yeung et al., 2000). The nuclear lamins essential for nuclear structural 
integrity (Dalton et al., 1995), proteins o f the retinal visual signal transduction system 
(transducin y subunit, cGMP phosphodiestrase a , and rhodopsin kinase) (Gibbs et al.,
1994), the human homologue of the yeast molecular chaperone YDJ1 (Caplan et al.,
1992), the skeletal muscle phosphorylase kinase, as well as other proteins yet to be 
identified or whose precise function is unknown (for example Pxf, RhoE, and Rap2) 
(Foster et al., 1996) are all thought to be famesylated (Gibbs and Oliff, 1997).
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In previous studies, researchers found that FTIs inhibit the famesylation o f one or 
more non-Ras proteins such as Rho B to exert their anti-tumor effects (Cox, 2001;
Rowell et al., 1997; Whyte et al., 1997). Protein prenylation is catalyzed by three 
different enzymes that recognize both the isoprenoid and the acceptor protein: FTase 
(famesyl transferase) and GGTase (geranylgeranyl transferase) I and II (Casey and 
Seabra, 1996). However, the specificity o f these enzymes for their substrates is not 
absolute. Thus, it appears that proteins usually modified by geranylgeranyl pyrophosphate 
(GGPP) may be prenylated by famesyl pyrophosphate (FPP) and vice versa, given the 
appropriate circumstances (Guijarro et al., 1998). Previous investigations into the 
biologic mechanism of the growth inhibition of Ras-transformed cells have shown that 
famesylation o f K-Ras and N-Ras is more resistant to FTase inhibitors than famesylation 
o f H-Ras (James et al., 1995; Nagasu et al., 1995; Sun et al., 1998). In the absence o f 
FTase inhibitors, all Ras proteins are present only in the famesylated form. However, K- 
Ras and N-Ras (but not H-Ras) become geranylgeranylated by GGTase I in vivo in a 
dose-dependent manner when intracellular famesylation is inhibited by an FTase 
inhibitor (Rowell et al., 1997; Whyte et al., 1997). Subsequently, both FTase and 
GGTase I inhibitors are required for inhibition of K-Ras processing (Lemer et al., 1997; 
Sun et al., 1998). Like K-rasB and N-ras, the low-molecular-weight protein Rho B also 
can be either famesylated or geranylgemylated (Armstrong et al., 1995; Casey and 
Seabra, 1996). Recently, it has been suggested that the antitransforming effects o f FTIs 
are mediated at least in part by alteration o f famesylated Rho proteins, including RhoB 
(Adjei, 2001; Chen et al., 2000; Lebowitz and Prendergast, 1998). In contrast to Ras 
proteins, RhoB exists normally in vivo in a famesylated (RhoB-FF) and a
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geranylgeranylated version (RhoB-GG). Treatment with FTIs results in a loss o f RhoB- 
FF and a gain o f RhoB-GG (Du et al., 1999).
Arglabin-DMA also affected the growth of normal cells. Our studies show that 
this drug blocks the growth of tumor cells, irrespective of ras genotype, with limited 
toxicity toward normal cells (Hs27). It has been reported in the literature that FTIs can be 
less growth inhibiting in normal cells in vitro and have fewer side effects in animal and 
human studies (Kohl et al., 1993; Rowinsky et al., 1999). FTI treatment inhibits and 
reverses malignant transformation without severely affecting normal cells (Du and 
Prendergast, 1999). Interestingly, tumor cell lines with wild-type Ras were also sensitive 
to FTI. In contrast, nontransformed epithelial cell lines were far less sensitive. It has been 
suggested that nontransformed cells may produce a form of Ras that is isoprenylated even 
in the presence o f FTase inhibitors (Nagasu et al., 1995; Emanual et al., 2000). 
Additionally, this phenomenon may be due to functional redundancy within the Ras 
family (Reuter et al., 2000). The genetic ablation o f FPTase does not cause the yeast cells 
to die. These observations provided evidence that inhibition o f FPTase, even though it is 
important to the function of a number o f proteins other than Ras, would not be toxic to 
normal cells (Gibbs and Oliff, 1997).
Preclinical studies showed that Arglabin-DMA, a sesquiterpene y-lactone, 
competitively inhibits the binding of famesyl diphosphate to FTase and may inhibit the 
function o f other famesylated cell proteins such as rho and related cytoskeletal proteins
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(Shaikenov et al., 2001). Our studies with add-back experiments examinated the possible 
explanation that Arglabin-DMA, as a sesquiterpene y-lactone, may affect the synthesis of 
cholesterol and suppress protein prenylation, particularly inhibition o f FTase and the 
oncogenic activated ras protein. Geranyl pyrophosphate and famesyl pyrophosphate, 
respectively, are intermediates in the synthesis of monoterpene and sesquiterpenes (Elson,
1995). It is been reported that the monoterpene, limonene, and the sesquiterpene, (3- 
lonone, suppress HMG-CoA reductase activity and lower the level o f low-density 
lipoprotein (LDL) cholesterol (Crowell et al., 1991), causing differentiation o f tumor 
cells (Haag et al., 1992). The secondary action of assorted isoprenoids is the direct 
inhibition of the protein isoprenyl transferase activities. These isoprenoids markedly 
suppress the growth of tumors in vitro and in vivo; the growth o f the host animal is not 
impaired (Elson, 1995). Arteminolide, a sesquiterpene lactone from Artemisia rulvatica, 
shows selective inhibitory activity against rat FTase (Lee et al., 1998).
Our data from add-back experiments proved that Lovastatin acts by inhibiting 
geranylgeranylation and not famesylation of target proteins. Lovastatin induced an 
accumulation of unmodified Ras and caused an up-regulation o f both RhoB and Rapl A 
(Holstein et al., 2001). HMG-CoA reductase inhibitors, including Lovastatin, decrease 
the overall synthesis of final products derived from the isoprenoid biosynthetic pathway, 
including cholesterol, dolichol and ubiquinone (Corsini et al., 1995). In one study, 
researchers examining the effects o f Manumycin A, an FPP analogue, found that the 
mechanism of action of Manumycin A did not involve the biosynthesis o f intermediates 
o f the cholesterol biosynthetic pathway and did not affect the synthesis o f cholesterol
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(Nagase et al., 1996). Furthermore, Manumycin A is cytotoxic and induces apoptosis in a 
human cell line derived from a colorectal cancer which expresses a wild-type K-ras gene 
(Di Paolo et al., 2000; Yeung et al., 2000). This effect is obtained by inhibition of ras 
famesylation that reduces signal transduction through the MAPK (the mitogen-activated 
protein kinase)/ERK (Signal-related kinase) pathway, without affecting protein 
geranylgeranylation or the synthesis o f final products of the cholesterol synthesis (Di 
Paolo et al., 2000). The analysis of add-back experiments in HCT 116 or HT-29 cells 
showed that Manumycin A, as a famesylation inhibitor, had no effect, similar to the 
results o f Arglabin-DMA on protein famesylation and geranylgeranylation. It was shown 
that Arglabin-DMA did not affect the biosynthesis o f end products of isoprenoid 
metabolism, and the effect of Arglabin-DMA on cell growth does not require the 
presence of a mutated ras gene. Although results with two FTIs (Manumycin A and 
Arglabin-DMA) in add-back experiments were not modified specifically by either FPP or 
GGPP, it may also be possible that Arglabin-DMA, as a non-FTI, may have anti-tumor 
effects. However, we can not conclude that Arglabin-DMA had no effect on famesylation;
One would predict that Arglabin-DMA may inhibit the growth o f tumor cells by 
blocking signaling pathways emanating from Ras. One o f the best characterized o f these 
pathways is the MAPK cascade, which is activated following Ras/Raf interaction, or via 
the phosphatidylinositol 3-kinase (PI 3-kinase; PI(3)K) pathway. Small G proteins such 
as Ras, Rho, and Rac have been shown to regulate a wide spectrum of cellular functions, 
including cytoskeletal organization, membrane trafficking, transcriptional activation, and 
cellular transformation (Gibbs and Oliff, 1997; Porter et al., 1998). Many types of
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extracellular signals, especially those involving activation o f receptor tyrosine kinase and 
integrin receptors, trigger activation of small G proteins, which in turn activate a variety 
o f signalings. Ras, which is frequently mutated in human tumors, activates several 
signaling pathways, including the Raf/mitogen-activated protein kinase cascade and the 
PI 3-kinase/Akt pathway, resulting in malignant transformation in rodent fibroblasts (van 
Weering et al, 1998; Jiang et al., 2001).
Protein famesylation, catalyzed by a FTase, plays important roles in the 
membrane association and protein-protein interaction of a number o f eukaryotic proteins. 
Recent development of FTase inhibitors (FTIs) has led to further insight into the 
biological significance of famesylation in cancer cells. A number o f reports point to the 
dramatic effects FTIs exert on cancer cells. These can be classified into four distinct 
categories. First, FTIs inhibit anchorage-independent growth of a wide variety o f cancer 
cells (James et al., 1993; Kohl et al., 1993). Second, FTIs may cause Go/Gi cell cycle 
arrest, G2 /M cell cycle arrest, or have no effect on cell cycle progression changes, 
depending on the cell line examined (Vogt et al., 1997). Third, FTIs induce apoptosis of 
cancer cells when the cells are exposed to low serum conditions or are inhibited in their 
attachment to the extracellular substratum (Tamanoi et al., 2001). Four, FTIs are reported 
to affect the actin cytoskeleton and cell morphology (Suzuki et al., 1998; Tamanoi et al., 
2001). Clinical trials of FTIs are not complete; thus, how they selectively inhibit 
malignant cell growth remains uncertain. Our studies showed that in many respects, 
Arglabin-DMA looks like other chemical FTIs, but not as a FTI inhibiting famesylation.
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Given all these considerations, the potential role o f Arglabin-DMA in the inhibition of 
tumor cell growth certainly deserves further investigation.
A striking morphological effect o f Arglabin-DMA is its ability to cause cells to 
round up and detach in both colon tumor cell lines (HCT 116 and HT-29). Annexin V 
and Apoptosis dye-uptake assays were applied to detect early apoptotic cells with altered 
membranes to cause translocation of phosphatidylserine molecules to the exterior surface 
o f the cell membrane. These assays detected a significant increase in apoptotic cells in 
the floating group when compared to other groups (untreated group or attached group 
exposed with Arglabin-DMA). Although early phase apoptotic cells were detected in the 
attached groups in the Annexin V assay, these were not documented through photography 
due to the fact that the cells were dimly stained. However, the Apopereentage assay was ' 
used to show more effectively that the membrane had been altered and that early phase 
apoptosis occurred in attached cells.
During the late phase o f apoptosis, specific endonucleases create DNA fragments 
with double-stranded breaks, cleaving them into so-called domain-sized fragments (50- 
300 bp). The TUNEL assay allowed for identification of fragmented DNA. These assays 
showed that untreated cells or adherent cells treated with Arglabin-DMA did not exhibit 
this late apoptosis phenotype. As seen in the DNA fragmentation assay, Arglabin-DMA 
induces DNA fragmentation in the late phase of apoptosis in floating but not attached 
HCT 116 and HT 29 cells. After exposure to Arglabin-DMA in one o f apoptosis-
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detection assays, identification of dying apoptotic cells, early and late phase o f apoptotic 
cells increased greatly in the floating group, and nucleic in the early phase o f apoptosis 
were seen in the attached group. This demonstrated the ability o f Arglabin-DMA to 
induce the early and late apoptosis in floating cells and the early phase of apoptosis in 
attached cells. We did not conclusively determine whether or not detection o f apoptosis 
in floating cells is due to cells detaching, or if  the detaching cells were the result of 
apoptosis. However, measurement o f cell viability after Arglabin-DMA challenge shows 
that the early-detached cells can reattach upon replating in the absence o f Arglabin-DMA 
and grow identically to untreated control cells (data not shown). This suggests that 
apoptosis precedes detachment. The results indicate that the early phase apoptotic cells 
affected by Arglabin-DMA in the two colon tumor cell lines probably were detached and 
then preceded to the late phase of apoptosis. Therefore, Arglabin-DMA may lead to 
apoptosis, then to changes in the adherence properties o f cells, causing them to be shed 
from the substrate prior to identifiable apoptosis. This apoptosis may contribute to the 
antitumor effects of Arglabin-DMA in vivo.
We propose that the growth matrix-detached fraction o f HCT 116 or HT-29 cells 
treated in vitro with Arglabin-DMA were apoptotic. The results suggest that this 
apoptosis, in response to the loss of cell-to-cell and/or cell-to-matrix communication, 
may be analogous to "anoikis," (Frisch and Francis, 1994). Anoikis is the term for 
detachment-induced cell death: cells undergo apoptosis upon disruption of the 
interactions between integrins and proteins o f the extracellular matrix. Integrins are 
receptors that bind extracellular matrix proteins to the outside o f the cell. The
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extracellular matrix is responsible for tissue organization throughout the body. It is also 
becoming clear that matrix proteins regulate certain aspects of gene expression and the 
cell cycle. They also regulate apoptosis in epithelial cells (Frisch and Francis, 1994). 
Anoikis also occurs when epithelial cells are either not bound to the matrix via integrins, 
or bind to the wrong integrins (Boudreau et al., 1995).
The tumor suppressor gene, p53, regulates apoptosis following a variety o f stress 
stimuli (Bennett, 1999). P53-dependent apoptosis activates the apoptosome, a multimeric 
complex consisting of Apaf-1, cytochrome c, dATP/ATP and procaspase-9, via the so- 
called intrinsic pathway (Soengas et al., 1999). Our data demonstrated that floating cells 
exposed in vitro to Arglabin-DMA enter apoptosis. To examine the relationship between 
p53 and apoptosis, we proposed that Arglabin-DMA may induce p53-independent 
apoptosis. The drug may be able to induce an extrinsic pathway of apoptosis or may 
mediate a cross-talk mechanism between the apoptosis pathways, through Bid, one o f the 
Bcl-2 family. It was reported that epithelial cells undergo death receptor-dependent 
apoptosis when detached from the matrix, a process termed anoikis. Also, the cleavage of 
Akt/protein kinase B (PKB) by death receptor signaling contributes to anoikis (Bachelder 
et al., 2001). Anoikis was found to be activated through the Fas pathway by FasL, the so- 
called extrinsic pathway. FasL/Fas interaction, Fas-FADD complex formation, and 
caspase-8 activation precede the bulk o f anoikis in endothelial cells, and inhibition of any 
o f these events blocks anoikis (Aoudjit and Vuori, 2001). Other results have indicated 
that the death receptor adaptor molecule, FADD, may be involved in anoikis, as a 
dominant-negative truncated FADD, containing only the death domain, inhibits anoikis.
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Anoikis was also shown to be accompanied by an early activation of caspase-8, as would 
be expected for death receptor activation (Frisch and Screaton, 2001).
In epithelial cells of the intestine and other organs, activated Ras induces 
resistance to anoikis (Shao et al., 2000). Resistance to anoikis may facilitate the survival 
o f cancer cells during systemic circulation, aiding the formation of metastases (Douma et 
al., 2004). The nature o f the survival signals activated by integrin engagement and 
usurped by oncogenic Ras are still unclear. Recent studies have implicated that adhesion 
or transformation by ras oncogenes have been shown to protect epithelial cells from 
apoptosis through activation of PI 3-kinase and Akt/PKB (Khwaja et al, 1997). A Rho 
family member, Rac 1, inhibits anoikis in epithelial cells. Rac 1 -mediated cell survival 
strongly depends on PI 3-kinase activity. PI 3-kinase, acting through Akt/PKB, a 
subfamily o f serine/threonine protein kinases, is implicated as a key mediator o f the 
aberrant survival of Ras-transformed epithelial cells in the absence o f attachment, and 
mediates matrix-induced survival o f normal epithelial cells (Coniglio et al., 2001; Frisch 
and Francis, 1994). Recently, the neurotrophic receptor tyrosine kinase (RTK), TrkB, 
was identified as a potent and specific suppressor of caspase-associated anoikis and 
linked it to the promotion of metastases. TrkB triggered the activation o f PI 3-kinases 
which stimulate Akt/PKB, and this too was active in the TrkB-producing cells. The result 
was a blockade of caspase-associated anoikis and related forms o f cell death. PI 3-kinases 
also drive numerous other cellular functions associated with metastasis (Liotta and Kohn, 
2004; Douma et al., 2004). It would be of interest to characterize Trk B effects in the 
Arglabin-DM-treated cells.
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In general, inhibition of cell growth by FTI in human tumor cells results in Go/Gi 
cell cycle block, G2/M cell cycle arrest, or has no effect on cell cycle progression (Vogt et 
al., 1997). One aspect o f FTI biology that is poorly understood is the ability o f these 
drugs to induce cancer cell growth arrest at the G2 /M phase o f cell cycle (Mazzocca et al., 
2003). In the present study, both human colon tumor cell lines showed cell accumulation 
at the G2 /M phase of the cell cycle following Arglabin-DMA treatment. Flow cytometry 
results indicated that these cells were tetraploid. Effective growth inhibition by FTI L- 
744,832 correlated with the accumulation of cells with a tetraploid (4n) DNA content and 
high levels o f cyclin Bl/cdc2 kinase activity, implying cell cycle arrest downstream from 
the DNA damage-inducible G2/M cell cycle checkpoint (Song et al, 2000). Treatment of 
a lung cancer cell line (A-549) with the protein famesyl transferase inhibitor Lonafamib 
(SCH66336) resulted in an increase o f G2 /M phase cells. It was shown that prophase and 
metaphase cells accumulated (Jiang et al., 2000). The inhibition o f CENP-E famesylation 
by FTI results in the alteration o f the microtubule-centromere interaction during mitosis 
and results in the accumulation of cells prior to metaphase (Ashar et al., 2000). It would 
be that Arglabin-DMA may associate with proteins involved to cell cycle or other 
famesylation proteins to induce human colon cancer cell growth arrest at the G2 /M phase 
o f cell cycle.
As discussed previously, Arglabin-DMA appears to induce apoptosis in a p53- 
independent manner; p53, a tumor suppressor protein, acts also in late Gi phase. If DNA 
damage has occurred, p53 accumulates in the cell nucleus and induces the p21-mediated 
inhibition o f cyclin D/cdk. Mdm2, by facilitating the nuclear export/inactivation o f p53,
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becomes part o f an inhibitory feedback loop that inactivates p21 -mediated Gi arrest. p53 
prevents the cell progressing to the S phase (Momand et al., 2000). Also, p53 participates 
in the regulation of G2/M. The progression into M phase requires Cdc2 which can be 
inhibited by p21 (Cyclin dependent kinase inhibitor), GADD45 (a p53-regulated stress 
protein), or 14-3-3a (adapter protein). p53 regulates the expression o f these inhibitory 
proteins to induce growth arrest (Hermeking et al., 1997; Liu and Kulesz-Martin, 2001). 
Both cell lines, having different Ras and p53 status, similarly induce cell cycle arrest at 
the G2 /M phase. It is therefore assumed that Arglabin-DMA may affect the arrest of 
G2 /M phase in cell cycle without involvement o f the p53 protein.
In flow cytometry analysis after the exposure of Arglabin-DMA for one day, our 
results did not show DNA content characteristic o f apoptotic cells (e.g., position o f the 
sub-Gi peak on the DNA content frequency histograms). In analysis o f DNA 
fragmentation, the floating groups, after treatment with Taxol in HCT 116 or HT 29 cells, 
showed ladder bands o f DNA after one day incubation. However, DNA ladder bands 
were not found in the floating group with Arglabin-DMA. It may be reasoned that flow 
cytometry analysis does not show the sub-Gi peak on DNA content frequency histograms.
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CONCLUSION
We conclude that Arglabin-DMA has specific cytotoxic effects in the two human 
colon tumor cell lines and in comparison to other antitumor drugs, less cytotoxicity to 
normal cells in vitro. Also, the drug has a marked effect on the morphology and the 
growth of both mutant K-ras and wild-type ras human colon tumor cell lines. Arglabin- 
DMA does not affect the biosynthesis o f the cholesterol pathway. Our studies do not 
support that Arglabin-DMA acts to inhibit tumor cell growth as a FTase inhibitor. One 
possible explanation is that Arglabin-DMA may inhibit the processing o f other 
famesylated proteins or may block signaling pathways emanating from Ras. However, it 
certainly deserves further attention. In our studies, Arglabin-DMA induces apoptosis after 
cellular rounding and detachment as a striking morphological effect in human colon 
tumor cell lines. The mechanism involved may be anoikis as cells undergo apoptosis 
upon disruption of the cell-matrix interaction. This apoptosis is induced in a p53- 
independent manner. It may also be induced via an extrinsic (death receptor) pathway. 
Finally, Arglabin-DMA induces G2/M cell growth arrest in human colon tumor cell lines 
(HCT 116 and HT-29). The utility o f this drug in combating cancer remains an attractive, 
possibility, although more work will be required to elucidate its mechanism of action.
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